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Abstract 
Anabolic-Androgenic steroids (AAS) are synthetic derivatives of testosterone. While they 
previously were associated mostly with use among professional athletes, the recent decades 
have seen a spread of AAS use to the general population. Heightened aggressiveness is one of 
the most commonly reported side effects of AAS use; however, the reasons behind this 
association have remained elusive. AAS have recently been shown to lead to neurochemical 
alterations in brain areas important for the regulation of aggression, as well as frontal areas 
important for executive functions. The aims of this study were to investigate aggression and 
levels of executive functioning in long-term AAS users. AAS users with long-term AAS 
using careers (defined here as 1 year of cumulative use or more) and non-AAS using 
exercisers were recruited from local gyms and via online forums. The assessment included a 
semi-structured interview concerning demographic data, exercise habits, self-reports of side 
effects and pattern of AAS use. Based on this data, estimated lifetime doses of AAS were 
calculated. Other aspects of pattern of AAS use were age of onset, total duration of use, 
concomitant drug abuse and AAS dependence. Aggression was assessed using the Buss Perry 
Aggression Questionnaire (BPAQ), which produces four subscales on different aspects of 
aggression. Executive functions were assessed using three commonly used 
neuropsychological tests; the Color Word Interference Test (CWIT), the Trail Making Test 
(TMT) and the Attentional Network Test (ANT). The results showed a significant and strong 
main effect of AAS use on several measures of aggression. AAS users with no history of drug 
abuse displayed significantly higher levels of aggression than controls. Furthermore, 
estimated lifetime dose, age of onset and duration of use correlated with levels of aggression. 
Findings on executive functions were somewhat more ambiguous. AAS users performed 
worse than controls on measures of executive inhibition and executive control. No differences 
were seen on tests of cognitive flexibility. It is concluded that AAS users display significantly 
higher levels of aggression compared to non-AAS using individuals, and that these levels are 
associated with a more severe pattern of AAS use. Furthermore, this investigation provides 
evidence that AAS users display lower levels of executive inhibition and control, but not 
flexibility. The implications of this finding for the association between AAS use and 
aggression are discussed, and suggestions for future research are presented. 
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1 Introduction 
Anabolic androgenic steroids (AAS) are synthetic derivatives of testosterone, designed to 
maximize the anabolic tissue building effect, compared to the androgenic effect, as well as to 
prolong the metabolic half-life thus increasing efficacy (Clark & Henderson, 2003). AAS has 
been thoroughly shown to increase tolerance for exercise (Tamaki et al., 2001) and increase 
lean body mass and physical strength (Hartgens & Kuipers, 2004). In addition to being used 
by exercisers for muscle gain, AAS are also used therapeutically in the treatment of a range of 
medical conditions, such as HIV, osteoporosis and hypogonadism (Quaglio et al., 2009). All 
AAS are thought to have some androgenic activity, and bind to the androgen receptors widely 
distributed throughout the brain (Clark & Henderson, 2003; Roselli, 1998; Pomerantz et al., 
1985).  
There are three main chemical families of AAS (Skårberg 2009; Oberlander & 
Henderson, 2012); C-17β-ester derivatives, usually administered orally, with a rapid effect. 
Examples of substances in this category are testosterone propionate, cypionate, enanthate and 
undecanoate. The second group, 19-nortestosterone derivatives, has a greater long-term effect 
and these substances are usually injected. Examples of substances in this group are 
nandrolone phenylpropriate, nandrolone decanoate and methenolone enanthate. Substances in 
the third group, 17α-alkyl derivatives, are usually taken orally.Substances in this group 
include stanozolol, oxymetholone, norethandrolone and danazol.  
 Like the AAS substances, the AAS users themselves have also been conceptualized 
into three different categories (Corcoran & Longo, 1992); Athletes, concerned with increasing 
their performance in sports; aesthetes, concerned with bettering their physical appearance; and 
lastly, fighting elite, use AAS to increase their fighting prowess and intimidation qualities. 
This last group includes career criminals, such as torpedoes, robbers and drug dealers. This 
categorization of course has more permeable boundaries as some users can belong to two or 
more of these groups. Cornford, Kean & Nash (2014), for example, interviewed AAS users 
with concomitant heroin use, and found that many of these individuals used AAS both as a 
way to fight weight-loss associated with heroin use as well as to increase their muscular 
strength to better function in their social context where violence and abuse is commonplace. 
A recent meta-analysis of the global epidemiology of AAS use found recreational 
sportspeople to be the group with the highest prevalence of AAS use, surpassing professional 
athletes, inmates/arrestees and drug users (Sagoe et al., 2014). Thus, it is evident that AAS 
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use is not just restricted to criminal subcultures, but may be a health concern in the general 
public as well.  
1.1 History 
Over 6000 years ago, humans discovered that castration made male animals easier to 
domesticate, and since then the source and effect of testosterone has been widely known 
(Freeman, Bloom & McGuire, 2001). The first scientist who tried to exploit the masculinizing 
effect of testosterone was the psychologist and neurologist Charles-Édouard Brown-Séquard, 
who injected himself with a fluid prepared from extracts from the testicles of guinea pigs and 
dogs. Consequently he reported rejuvenation, increased sexual prowess, increased mental 
capacities and appetite, although questions have been raised concerning the biological basis 
for these claims (Dotson & Brown, 2007).  
Testosterone was first isolated and characterized in Germany in the 1930s, and soon 
several derivatives and similar compounds were synthesized to what is now known as 
anabolic androgenic steroids (Kanayama, Hudson & Pope, 2009a). There exists anecdotal 
evidence that German soldiers during world war II were given AAS to increase their 
aggressiveness in combat, and that concentration camp survivors were given AAS to rebuild 
muscle mass (Wade, 1972). AAS use quickly spread to professional athletes, and in 1954 
AAS were used by the Russian team in the weightlifting championship in Vienna (Wade, 
1972). In the 1980s AAS use began to spread outside the confines of professional sports, and 
the general public saw the release of handbooks on AAS use, such as Daniel Duchaine’s 
Original Underground Steroid Handbook, and Nathan Philips’ Anabolic Reference Guide 
(Kanayama, Hudson & Pope, 2008). Today, there is evidence to support the effects AAS have 
on increasing lean body mass, muscle size and strength (Evans, 2004). On the other hand, 
AAS is well known to produce adverse psychiatric and social effects (Oberlander & 
Henderson, 2012). A diverse range of medical side effects has also been associated with AAS 
use, such as hepatic problems, impotency, gynecomastia and cardiovascular disorders 
(Hartgens & Kuipers, 2004; Golestani et al., 2011). AAS use evidently is a double-edged 
sword. 
 The association between AAS and acts of violent aggression first caught the public’s 
eye in the United States in the late 1980s, with the advent of case-reports involving grisly acts 
of violence committed by young AAS-using men with no prior history of violence (Thiblin, 
Nyberg & Moberg, 2013). 
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1.2 Epidemiology/prevalence: 
A recent report about AAS use in Norway (Sandøy, 2013) concluded that lifetime prevalence 
in studies of AAS use in Norway tend to hover around 2 %. In the material for SIRUS’ report, 
0.6 % of adolescents and 1.6 % of young adults reported having used AAS, and men report 
significantly higher prevalence than women. The nature of their use was assessed with 
questions regarding frequency of use and use within the last six months. Among adolescents 
37 % of those who reported AAS use had done so 1-4 times, while 35 % had used AAS more 
than 25 times. Half of them had not used AAS within the last six months. Similar rates were 
obtained for young adults. The willingness to use AAS to get a muscular body was also 
assessed; 7.0 % of the men and 2.2 % of the women reported that they would to some extent 
be willing to use AAS, even considering the potential health risks. Pallesen and colleagues 
(2006) found prevalence rates of 3.6% for boys and 0.6% for girls among 1351 high school 
students in Hordaland, Norway. In addition to this, they found that 27.9% reported having at 
least one acquaintance that used or had used AAS. It should be noted that these studies may 
underestimate the prevalence of AAS as the samples are young quite young. One study of 
1,955 AAS users showed that the majority initiated AAS use after adolescent, with a mean 
age of onset of 25.81 (SD=8.26) years (Cohen et al., 2007), indicating that studies of 
adolescents and young adults may not be the most appropriate source of information about the 
prevalence of AAS use in the general population.  
 Concerning the global epidemiology of AAS use, Sagoe and colleagues (2014) in a 
meta-analysis found overall life time-prevalence to be 3.3%. Prevalence for men was 
significantly higher than for women (6.4% vs. 1.3%). They also found a higher prevalence 
among younger (<=19 years old, p%=2.5) than older participants (>19 years old, p%= 1.9).  
These authors also found prevalence rates to vary between regions, with Asia being the region 
with the lowest prevalence rates (0.2%). The large majority of AAS users are men that are 
recreational sportspeople (Sagoe et al., 2014; Ip et al., 2011). 
 Some evidence seems to indicate that AAS use has been on the rise for the last 10-15 
years. Lood and colleagues (2012) found that the number of inmates who was detected using 
AAS increased dramatically from 1999 to 2009. Sagoe and colleagues (2014) also reported a 
steady increase in the global prevalence of AAS use from the 1990s to the 2000s.  
Taken together, prevalence rates of AAS use vary by region and study (Sagoe et al., 
2015), and it has been on the rise for the last 10-15 years. This steady increasing prevalence 
rate is a cause for concern considering the wide range of health issues associated with AAS 
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use (Golestani et al., 2011; Oberlander & Henderson, 2012). The relatively high prevalence of 
AAS use among adolescents (Harmer, 2010) is especially troubling in light of evidence about 
the impact of adolescent AAS initiation on brain development and social behaviors later in 
life (Schulz et al., 2004; Salas-Ramirez, Montalto & Sisk, 2010, Cunningham, Lumia & 
McGinnis, 2013), although some evidence indicate that most AAS users initiate use after 
adolescence (Cohen et al., 2007). The variation in prevalence rates as well as the inherent 
biases concerning self reports of performance enhancing substances (Kanayama, Pope & 
Hudson, 2001) make it difficult to draw strong conclusions regarding the prevalence of AAS 
use in the general population.  
1.3 Pattern of use 
Unlike use of many other illicit drugs, the use of AAS is often elaborately planned in advance. 
A typical pattern of use includes periods of about 6-12 weeks on AAS, called “cycles”, 
followed by a period without use in order to minimize adverse side effects (Brower, 2002). 
Within these “cycles”, AAS users employ techniques called “plateauing” and “pyramiding”. 
Plateauing involves using a substance for some time, and then replacing it with another in 
order to reduce tolerance to a particular substance. Pyramiding involves beginning cycles with 
relatively small weekly doses, and then continually escalating the number and quantity of 
AAS substances until a maximum dose is reached either at the middle or toward the end of 
the cycle (Trenton & Currier, 2005). It is not surprising then, that the majority of AAS users 
report consumption of a wide variety of different AAS substances, and rarely sticks to one or 
two. In order to escape periods of hypogonadism associated with withdrawal symptoms such 
as decreased or absent libido, erectile dysfunction and symptoms of depression (Kanayama et 
al., 2015), many AAS users employ the practice of “cruising”. This involves continually using 
low doses of AAS between cycles 
 Another common feature of AAS use is polypharmacy; combining AAS use with other 
substances, either to increase the effects of AAS or combat the negative side effects of AAS 
(Sagoe et al., 2015). Substances commonly used in combination with AAS include other 
performance enhancing drugs (Kanayam & Pope, 2012), but AAS use is also highly 
associated with use of recreational drugs of abuse (Buckman, Farris & Yusko, 2013). Opioid 
use is especially prevalent among AAS using individuals (Kanayama, Hudson & Pope, 2009a; 
Nyberg & Hallberg, 2012). Alcohol consumption is also highly prevalent in AAS users 
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(Dodge & Hoagland, 2011; Pallesen et al., 2006). AAS use, then, is apparently not associated 
with a healthy athletic lifestyle. 
1.4 AAS dependence 
In recent years, it has been increasingly recognized that AAS users may develop a 
dependency toward AAS (Kanayama et al., 2009a). As no instances of AAS dependence have 
been identified in persons treated with therapeutic doses (Brower, 2002) the risk for 
developing a dependency seems to be constricted to users of supraphysiologic doses. Many 
who have used AAS in the course of their life only go through a couple of cycles, amassing to 
less than 12 months of cumulative use, while others develop a pattern in which they continue 
using without off-periods between cycles, or “off” periods with relatively smaller doses of 
AAS (i.e. cruising; Kanayama et al., 2009a). Contrary to many other illicit drugs, AAS does 
not lead to rapid increases in dopamine levels, causing a euphoric feeling (van Amsterdam, 
Opperhuizen & Hartgens, 2011). The rewards of AAS use come in a more delayed fashion, as 
larger muscles (Kanayama et al., 2009b). Negative reinforcers of AAS have also been 
identified, experienced during withdrawal. These include steroid craving, fatigue, depressed 
mood, restlessness, loss of appetite, insomnia, reduced sex drive, headache and muscle and 
joint pain (Brower, 2002; van Amsterdam, Opperhuizen & Hartgens, 2011; Quaglio et al., 
2009). Many users also report fear of losing muscle mass, physical strength and physical 
attractiveness to be concerns over cessation of AAS (Cohen et al., 2007). Thus, both negative 
and positive reinforcers can work in tandem to create a dependence-syndrome in some AAS 
users. The prevalence of dependence among AAS users has been estimated to be as high as 30 
% (Kanayam et al., 2009a). 
1.5 AAS as a general health problem 
Sandøy (2013) concludes that prevalence rates for Norway tend to hover around 2 %, and 
reports that about a third of self-reported AAS users had used AAS more than 25 times. Long-
term AAS use, then, is apparently not highly prevalent in Norway, although one has to 
consider the possibilities of underreporting (Kanayama, Pope & Hudson, 2001). The 
estimated extent of a public health problem should not solely be based on its prevalence 
though. It should also take into consideration the severity of the problem for those it may 
concern as well as a closer evaluation of who it really does concern. The by now widely 
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accepted association between AAS and aggression (Trenton & Currier, 2005) indicates that, 
while AAS use may be detrimental for the user itself, individuals in close proximity may also 
be at risk for side effects of AAS use (e.g. significant others; Choi & Pope, 1994). These 
individuals are not covered in prevalence studies. Taken together, the extent of AAS use as a 
public health problem may be larger than low prevalence rates might imply.  
1.6 Aggression 
The concept of aggression is multifaceted and wide. As it is a central theme in this 
investigation, it is worth closer scrutiny. A wide variety of different definitions of aggression 
have been proposed, but generally it has been classified into two distinct subtypes (Ramirez & 
Andreu, 2006); hostile aggression, in which the intent of the aggressive behavior is harm or 
distress toward the target of the aggressive behavior, and instrumental aggression, in which 
aggression is used more indirectly as a tool to achieve some reward or profit. The former is 
seen as more impulsive, affective and thoughtless, while the latter is considered more though 
out and cold blooded. A tripartite division of aggression into behavior (physical and verbal 
aggression), emotion (feelings of anger) and cognition (hostility, ill will) has been suggested 
as an expansion of aggression beyond behaviors (Buss & Perry, 1992).  
 A framework called the I
3
-theory (pronounced I-cubed) has been proposed to help 
researchers understand how a wide range of risk factors act and interact in social interactions 
that may or may not lead to aggressive outcomes (Slotter & Finkel, 2011). This theory 
describes how three classes of factors influence the processes that may lead to aggressive 
behaviors. These factors are: Instigating factors (e.g. insults, goal obstruction, social rejection) 
that may trigger a hostile situation. Impelling factors (e.g. personality characteristics, 
attitudes, beliefs) that determine the strength of the aggressive impulse experienced by the 
individual. Finally, inhibiting forces (e.g. dispositional self-control, negative beliefs about 
aggression) are factors that determine whether the individual will override the aggressive 
impulse and reconsider the use of aggression. I
3
-theory also states that these factors interact 
with one another, across classes. This view was supported by a series of studies that tested 
hypotheses derived from the I
3
-theory, concerning how these classes of factors interact to 
produce intimate partner violence (Finkel et al., 2012). In one of these studies, 50 couples 
were measured on trait aggressiveness (Impelling factor), inhibition (a computerized Stroop 
task; Inhibitiong factor) and completed a questionnaire diary at home about how much their 
partner had provoked them that day (Instigating factor). Intimate partner violence was 
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assessed once a day, by presenting each participant with a computerized voodoo doll 
representing their partner and counting the number of pins they chose to insert into the doll. 
Results indicated that all three factors interacted to promote partner violence; more 
provocative behavior than usual, high trait aggressiveness and low executive inhibition 
interacted to increase the number of pins inserted into the virtual voodoo doll. 
1.7 AAS and aggression 
1.7.1 Results from animal studies 
The major methodological advantage of using animal models when investigating the 
association between AAS and aggression is that researchers can control for pattern of use in 
the subjects. At the same time, this is a weakness, in that it does not accurately reflect human 
AAS use patterns (McGinnis, 2004). Thus, many animal studies use a “cocktail” of different 
AAS in order to more accurately mirror human use, but then again, this hinders the task of 
determining individual AAS effects of different substances (Lumia & McGinnis, 2010). 
Another major methodological advantage is the ability to randomly assign subjects to AAS 
use conditions. 
Long-term AAS use initiated during adolescence has been shown to increase 
aggressive responding in rats (Olivares et al., 2013, Long et al., 1996; Farrell & McGinnis, 
2004; Salas-Ramirez, Montalto & Sisk, 2010; Salas-Ramirez, Montalto & Sisk, 2008; Wood 
et al., 2013). A study that directly compared long-term AAS use and aggressive responding in 
rats treated during adolescence and adulthood, found equally high levels of agonistic 
aggressive responses in both groups compared to controls. However, they observed 
significantly less submissive responses (such as escape-dashes) in rats treated during 
adolescence (Salas-Ramirez, Montalto & Sisk, 2010). Salas-Ramirez, Montalto & Sisk (2008) 
also compared the acute effect of AAS on aggression in adults versus adolescents, and found 
significantly higher levels of aggressive responding in adolescents compared with adults. In 
this study, the difference in aggression between adults treated with AAS compared to 
controls, only tended toward significance. They concluded that the adolescent brain might be 
more vulnerable to the effects of AAS on the central nervous system than the adult brain.  
Several studies have investigated neurochemical alterations following AAS use. AAS 
binds to the androgen receptors, found in the amygdala, hypothalamus, the stria terminalis, 
hippocampus, cingulated cortex, parietal cortex and cerebellum of rhesus monkeys 
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(Abdelgadir et al., 1999). Some AAS can also be aromatized into estrogens with agonistic 
activity at the estrogen receptors, found throughout the brain (Henderson et al., 2006; Panetti, 
Porter & Henderson, 2009; McEwen, 2001). Both androgens and estrogens have been shown 
to play important roles in aggression in mice (Sato et al., 2004; Scordalakes & Rissman, 
2003). Chronic exposure of AAS in rats has been shown to lead to both acute and chronic 
alterations in GABAergic responding in the forebrain of mice (Henderson et al., 2006). 
Furthermore, this effect was dependent on the dose of AAS administered. This alteration has 
been shown to be modulated by both androgen and estrogen receptors (Penatti, Porter & 
Henderson, 2009). Hamsters exposed to AAS during adolescence have been found to display 
increased activity of vasopressin in the ventrolateral hypothalamus, the stria terminalis and 
lateral septum, brain areas associated with modulation of aggression (DeLeon, Grimes & 
Melloni, 2002). Thus, it is evident that AAS may act upon a wide variety of neurochemical 
systems in brain areas associated with modulation of emotional behavior and aggression, and 
that there is a complex relationship between the chemical structure of the AAS, exposure dose 
and age of the subject. 
The effects of AAS in combination with recreational drugs of abuse have also been 
investigated in animals. Long & colleagues (1996) treated rats with either an AAS 
(nandrolone), cocaine or a combination of these substances over a four week period. They 
found that rats receiving a combination of AAS and cocaine displayed increases in aggressive 
responding compared to rats treated with either substance alone. A comparable investigation 
has been done with nandrolone and amphetamine use (Steensland et al., 2005). These authors 
found that rats first treated with nandrolone, showed increased aggressive responding when 
treated with amphetamine three weeks after cessation of AAS injection, compared to rats only 
treated with amphetamine.  
Aggressive responding induced by AAS has also been shown to be dependent on the 
chemical structure of the AAS substance (McGinnis et al., 2002; Breuer et al., 2001). 
McGinnis and colleagues (2002) found that Testosterone Propionate (TP) increased 
aggression in adult male rats, while Nandrolone-treated (ND) rats did not differ from controls, 
and rats treated with Stanozolol (ST) actually decreased aggressive responding. ND was 
found to increase aggressive responding in male rats in an earlier study (Long et al., 1996), 
however, the authors of this study also noted that the effect of this particular AAS substance 
on aggression was smaller in magnitude than that observed with other AAS substances in 
earlier studies (Long et al., 1996, p. 850). A more recent investigation has also failed to show 
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an increase in aggression following ND-treatment (Wesson & McGinnis, 2006). Concerning 
the surprising finding that ST decreased aggressive responding, this has been corroborated in 
other studies (McGinnis et al., 2002; Breuer et al., 2001; Farrell & McGinnis, 2004; Martinez-
Sanchis et al., 1996; Wesson & McGinnis, 2006).  
A recent investigation sought to illuminate some of the causal pathways between AAS 
use and aggression. Wood and colleagues (2013) investigated the effect of AAS on aggressive 
motivation and impulsivity. They found no increase in aggression motivation in AAS treated 
rats, as seen by their unchanged willingness to allow an intruder rat into their cage compared 
to vehicle treated rats. Impulsivity was lowered in rats treated with AAS, measured by an 
increased preference of a larger, delayed reward. These findings indicate that AAS induced 
aggression is not a result of an increased desire to fight or loss of impulse control.  
There seems to be evidence in favor of the proposition that AAS may alter social 
cognitive processing in rats. McGinnis and colleagues (2002) in the study mentioned above 
found that AAS (TP) treated rats reacted significantly more aggressively than vehicle treated 
rats in response to physical provocation directed at the intruder rat. AAS treated rats have also 
been shown to react more defensively in response to relatively harmless stimuli (the 
experimenter’s hand) and show more fear reactions to other harmless stimuli (e. g. slight air 
puff in the back; Johansson et al., 2000).  
 Taken together, evidence for the effect of AAS on increased aggression has been 
thoroughly substantiated in animal research. Adolescent AAS exposure has been shown to 
produce a heightened level of aggression both acutely (Salas-Ramirez, Montalto & Sisk, 
2008) and in adulthood (Olivares et al., 2013, Farrell & McGinnis, 2004) as well as 
qualitatively different aggressive behavior, with fewer submissive responses compared to 
adult exposure (Salas-Ramirez, Montalto & Sisk, 2010). Evidence concerning the acute 
effects of AAS on aggression in adult exposure is more ambiguous than evidence on 
adolescents (Sala-Ramirez, Montalto & Sisk, 2008). There is also some evidence for an 
interaction between AAS use and use of other illicit substances (Long et al., 1996; Steensland 
et al., 2005), and that AAS induced aggression is not caused by an increased motivation to 
fight or lowered impulsivity (Wood et al., 2013). A kaleidoscopic picture emerges, with 
complex relationship between the chemical structure of the AAS substance, age of AAS 
exposure, sex of the AAS user and possible alterations in social cognitive processing. 
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1.7.2 Experimental studies in humans 
Experimental studies of AAS use in humans are restricted by ethical considerations that limit 
the conclusions that can be drawn from them. Firstly, one cannot ethically conduct an 
experiment where the doses administered are as large as those that have been observed in real-
life AAS users. Secondly, the length of use duration utilized in experimental studies cannot 
possibly approximate real situations where AAS users have been known to use for decades. 
On the other hand, experimental studies are unmatched in their ability to inform us about the 
causal links between acute and short term AAS use and aggression. This is a powerful 
advantage that makes the few studies of this kind invaluable sources of knowledge concerning 
the relationship between AAS use and aggression. 
The first prospective, double-blind, placebo-controlled study to investigate the effects 
of AAS on mood was performed in the early 1990s (Su et al., 1993). In this investigation, 20 
healthy volunteers were given, in bulks of three days per condition, first a placebo-baseline, 
then low AAS dose (40 mg methyltestosterone/day), high (240 mg methyltestosterone/day) 
followed by a placebo-withdrawal phase. These authors thus measured the acute effects of 
AAS use. When in the high-dose condition, participants reported significantly increased 
levels of self-reported irritability and distractibility, while violent feelings and anger showed a 
trend toward significance. Pope, Kouri and Hudson (2000) used a randomized, double blind 
experimental design to investigate the effects of AAS use, mania and aggression. They 
injected study participants with either testosterone or a placebo control with increasingly 
higher doses, ranging from 150 mg/week to 600 mg/week, over six weeks and measured 
aggression using the Buss Perry Aggression Questionnaire (Buss & Perry, 1992) and the Point 
Subtraction Aggression Paradigm (PSAP, Cherek et al., 1996). Manic symptoms were 
measured using the Young Mania Rating Scale (YMRS, Young et al., 1978) as well as daily 
diaries at home, to be filled out by both participants and significant others. The results from 
this investigation showed that participants showed significantly increased measures of manic 
symptoms as well as aggression, as measured by the PSAP. However these findings were not 
uniform as most participants showed no significant change while a few showed marked 
changes. The participants showed no significant changes in aggression measured by the Buss 
Perry Aggression Questionnaire except the Verbal Hostility subscale. The results were 
unrelated to the participants’ previous exposure to AAS or regular weight lifting, but 
participants displayed elevated symptoms with higher dosages. Another study (Tricker, 
Casaburi et al., 1996) found no relationship between AAS exposure and aggression or 
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changes in mood, however this investigation also used relatively small doses (600mg 
testosterone enanthate/week), as well as only one AAS substance, compared to the wide 
variety of combinations often reported by real life AAS users. These authors conclude that the 
findings could also be a result of their strict screening procedure, excluding people with sings 
of previous psychiatric or drug problems.  
Taken together, these studies are informative concerning the acute effects of moderate 
(Pope, Kouri & Hudson, 2000) to high (Su et al., 1993) doses of AAS. However, as seen in 
these studies the use of lower doses seems to produce less severe symptoms, which might 
indicate that the results tend to underestimate the effects of real-life AAS use. The main point 
is that short-term AAS use seems to increase levels of aggression in a dose-dependent 
manner. 
1.7.3 Naturalistic studies 
Unlike experimental studies, naturalistic studies can investigate the effects of long-term AAS 
use. Like experimental studies, however, naturalistic studies also have some inherent 
methodological concerns, some of which might be considered more troublesome when 
investigating the association between AAS and aggression. One can hypothesize that social 
desirability bias may be especially common in these studies (Saunders, 1991). Although 
naturalistic studies necessarily are only correlational, impeding the causal conclusions 
regarding the relationship between AAS use and aggression that can be drawn from them, 
they nonetheless serve to illustrate the need to further elucidate the nature of this relationship. 
Case studies were the earliest source of insight on the apparent relationship between 
AAS use and aggression and violent acts (Thiblin, Nyberg & Moberg, 2013). Pope and Katz 
(1990) interviewed three AAS users who attributed their violent behaviors, including murder, 
to their use of AAS. Another early case report (Dalby, 1992) describes a young man, who 
following a five week period of increasing doses of the AAS Equipoise, experienced a 
significant change in personality that persisted long after cessation of AAS use, and that 
culminated in armed robbery. Pope and colleagues (1996) reported a case in which a 16-year-
old boy was convicted of killing his 14-year-old girlfriend following AAS use. This boy had 
no record of antisocial behavior prior to AAS use, but when he used steroids he showed a 
striking change of character and started to get in trouble with the police. These authors also 
described how a 27-year-old man intently used AAS to increase his confidence and feeling of 
invincibility needed to deal heroin, and that he would not be able to do this without AAS. An 
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investigation of two pairs of monozygotic twins, where one twin used AAS and the other did 
not, showed increased levels of hostility, aggressiveness and paranoid ideation in the AAS 
using twins (Pagonis et al., 2006b). Cooper and Noakes (1994, cited in Trenton & Currier, 
2005) longitudinally observed 12 bodybuilders using AAS, who displayed increases in 
antisocial behavior including violence and a tendency towards illegal and dangerous 
activities.  
Based on anecdotal evidence that partners of AAS users are at risk of becoming 
victims of AAS induced aggression, one study found that AAS users reported significantly 
more fights, verbal aggression and violence toward their wives and girlfriends when on AAS 
compared when off AAS a and compared to non-AAS using controls (Choi & Pope, 1994). 
Thiblin and Pärlklo (2002) performed a prospective longitudinal follow-up of police records 
of five known users of AAS, for which AAS use was the first illegal activity reported to the 
police. All of these participants were later convicted for more serious crimes, such as assault 
and drug dealing. This study is interesting in that the authors found that AAS use not only 
caused violent outbursts of impulsive aggression, but also marked an entry into criminal 
careers possibly catalyzed by AAS use.  
 A recent study from Norway (Jenssen & Johannessen, 2014) investigated whether 
contemplation of AAS use in itself was a risk factor for aggression. Four hundred students in 
Norwegian high schools (mean age; 16,8 years) completed questionnaires concerning AAS 
use and aggression (Aggression Questionnaire, Buss & Perry, 1992). Of these, 16 (4.0%) 
reported prior AAS use and 20 (5.1%) reported contemplating AAS use. These groups were 
compared to each other and the remaining students. Students who had previously used AAS, 
and contemplators reported significantly elevated levels of aggression compared to non-users, 
but the results failed to show a significant difference between users and contemplators. Thus, 
merely contemplating AAS use was a strong predictor for increased aggression as AAS use in 
itself.  
1.7.4 AAS and criminal offending 
A higher level of aggression in AAS users may ultimately manifest itself as various types of 
criminal offending, associated with personal suffering as well as great costs to society. The 
assessment of the relationship between AAS use and criminal offending is therefore an 
important area of research.  
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Beaver, Vaughn and Wright (2008) found a significant relationship between lifetime 
AAS use and involvement in acts of serious violent behavior (e.g. physical fights, stabbings) 
in young men, when controlling for age, previous antisocial behavior and concomitant drug 
use. Another investigation found an increase in criminal activity among users of AAS, with a 
concurrent misuse of other illegal drugs following onset of AAS use (Skårberg, Nyberg & 
Engström, 2010). In this study, onset of any type of drug increased the level of criminal 
offending, but onset of AAS use led to a sharper increase in criminal behavior. AAS has been 
shown to have an increased prevalence among substance users convicted of violent crimes 
compared to substance users committed of non-violent crimes (Lundholm et al., 2010). Lood 
and colleagues (2012) performed AAS screening on a total of 12 141 urine samples from 
suspects in police cases (6362 samples) and inmates in prison (5779 samples) over a period of 
ten years. AAS were detected in 33.5% of persons involved in petty drug offences, 38.8% in 
cases of driving under the influence of drugs and in 19.4% of cases involving violent crimes. 
On the other hand, a recent investigation cast doubt on the relationship between AAS and 
criminality (Lundholm et al., 2015). This investigation found that the strong association 
between AAS use and violent offending was reduced to non-significance when controlling for 
use of other substances. Controlling for IQ, psychological functioning (stress coping), ADHD, 
personality disorders and childhood socioeconomic status did not diminish the association 
further. Taken together, there are now several studies that show AAS use is prevalent in 
individuals convicted for various crimes, especially crimes involving drugs and violent 
offending. There is also evidence that indicates that AAS use in addition to use of other illicit 
drugs of abuse is a risk factor for increased rates of violent offending.  
There is an apparent discrepancy between qualitative studies where AAS tend to be 
highly associated with acts of violence, and quantitative studies which tend to be less 
conclusive concerning the strength and exclusivity of this association. This has been 
attributed to either to a low frequency of acts of violence in AAS users, or a link between 
AAS and violence which in some way masks this association in quantitative studies (Thiblin, 
Nyberg & Moberg, 2013). These authors suggest that AAS in and of itself might not be a 
powerful risk factor for acts of violence, but that a chronic AAS abuse might lower the 
threshold for committing these acts under the influence of other substances, such as alcohol 
and other drugs of abuse.  
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1.8 Executive functions and aggression 
Executive functions are top-down mental processes that among other things are important for 
impulse control, mental flexibility and selectively paying attention. Humans rely heavily on 
executive functions to successfully navigate the extreme complexity of human society. Three 
core executive functions have been identified (Diamond, 2013): Inhibition, working memory 
and cognitive flexibility. Briefly; inhibition pertains to the ability to control attention, 
behavior, thoughts and emotions, and instead use top-down processing to choose how to react 
to stimuli. Without inhibitory control, we would be unable to resist impulses and automatic 
responses. An aspect of inhibition that is of interest in the present discussion is self-control; 
being able to control one’s behavior. Working memory pertains to ability to hold and 
manipulate information in the mind (Baddeley & Hitch, 1994). Lastly, cognitive flexibility is 
the ability to mentally change perspectives, both spatially and interpersonally, as well as 
adjusting behavior in response to changing circumstances. While executive functions have 
been divided into these three domains, there is a heavy interdependency between them. Few, 
if any, cognitive tasks rely only on one kind of executive function (Diamond, 2013). For 
example, when cognitively shifting between two rule sets, you have to keep both sets in 
working memory, and use inhibition to inhibit the rule not currently in use.  
There is now a large research literature that demonstrates the importance of executive 
dysfunction in criminal offending. Although this field is trouble ridden with varying 
definitions and measurements of both executive functions and aggression, the common theme 
is that executive dysfunction, however defined, is related to criminality (Hancock, Tapscott & 
Hoaken, 2010). Domestic violence has been related to poorer performance on Trail Making 
Test B, compared to controls (Becerra-Garcia, 2015), and impaired executive functions in 
patients following Traumatic Brain Injury (Marsh & Martinovich, 2006). One study of 
criminal offenders found that performance on the inhibition condition of the Stroop task was 
significantly related to frequency and severity of violent offending, but not related to 
nonviolent offending (Hancock, Tapscott & Hoaken, 2010). Broomhall (2005) found 
impairments in inhibition and flexibility, as measured by respectively the Stroop 3 and 4, in 
offenders of reactive (impulsive, unplanned) and not instrumental (goal-directed, planned) 
aggression. One area of some dispute is whether executive dysfunction is more characteristic 
of violent offenders or of all individuals who engage in some form of criminal behavior 
(Hancock, Tapscott & Hoaken, 2010).  
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Impairments in executive functions have also been linked to aggression in the general 
population. Poorer inhibition has been found in persons with high trait aggression compared 
to persons with low trait aggression in a stop signal task with emotional stimuli (angry faces; 
Pawliczek et al., 2013). Set-shifting impairments have been associated with anger rumination 
and revenge planning (Gul & Ahmad, 2014). In the perspective of the I
3
-theory, executive 
inhibition has been labeled an inhibiting factor; high levels of executive inhibition can work 
to inhibit further escalation in an aggression filled situation by recruiting down-stream 
processing to override aggressive impulses (Slotter & Finkel, 2011). In support of this view is 
Finkel and colleagues (2012) in the study mentioned above, where a higher level of inhibition 
(better performance on a computerized version of the Stroop test) repressed the level of 
violence toward a virtual voodoo doll representing the person’s intimate partner.  
1.9 AAS and executive functions 
1.9.1 Evidence from human studies 
Only two studies have to date investigated the effects of long-term AAS use on cognition in 
humans. Kanayama et al. (2013) conducted a study where they performed neuropsychological 
assessment of long-term AAS users using the CANTAB-battery (Cambridge Cognition). 
They found no significant differences on the modules Choice Reaction Time, Rapid Visual 
Information Processing or Verbal Recognition Memory, which implies that psychomotoric 
speed, vigilance, sustained attention and verbal memory was not related to AAS use. On the 
test Pattern Recognition Memory AAS users made significantly more errors on immediate 
recognition compared to nonusers. This study provided the first evidence that long-term AAS 
use is associated with lower levels of cognitive functioning in some cognitive domains. 
Especially interesting was the finding that long-term AAS users displayed lower functioning 
on tests tapping working memory, an aspect of executive functioning, and the finding that the 
scores on these tests were negatively correlated with lifetime AAS dose. 
 Hildebrandt and colleagues (2014) compared on-cycle vs. off-cycle AAS users on 
measures of inhibitory control using an affective go/no-go task, and found on-cycle users to 
make more errors but respond faster than off-cycle users in response to emotional stimuli. 
This somewhat unexpected result was explained by a generally higher brain arousal, 
associated with heightened emotional reactivity, locomotion and alertness. They also found 
some differences on a computerized set-shifting task, indicating that on-cycle AAS users may 
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be poorer at planning and set-shifting. Findings from this study were interesting, however the 
samples used were very small (N=5 to 6), and must thus be considered preliminary. 
 
1.9.2 Evidence from animal studies 
While the literature on AAS and executive functions is sparse in animal models, it is 
somewhat less incomprehensive than the literature on humans. AAS has been shown to be 
associated with alterations in dopamine function in the prefrontal cortical-striatal circuitry 
(Wood et al., 2013). This alteration has also been noted in a study on the effect of AAS on 
dopamine response to cocaine (Kurling-Kailanto, Kankaanpää & Seppälä, 2010). The 
prefrontal cortical-striatal circuitry is important for executive functions, such as behavioral 
flexibility (Wallin & Wood, 2015) and risk-reward decision making (Simon et al., 2011). 
Alterations in this circuit may have implications for other tasks performed by the prefrontal 
cortices (Wallin & Wood, 2015). AAS use has also been shown to lead to alterations in brain 
nerve growth factor and GABAergic transmission in the forebrain of rats (Pieretti et al., 2012; 
Henderson et al., 2006). Wallin and Wood (2015) tested the assumption that AAS use may 
lead to a decrease in behavioral flexibility. These authors used a set-shifting and reversal 
learning paradigm on adolescent male rats. The results from this investigation showed that 
rats treated with AAS required significantly more trials to reach the criterion on several set-
shift tasks, and thus were impaired on behavioral flexibility compared to controls.  
A few studies have investigated the general effect of AAS on brain and cognition. As 
noted, the main point of action for AAS in the central nervous system are the androgen 
receptors and to a lesser extent the estrogen receptors (Clark & Henderson, 2003). These 
receptors are found in many areas of the brain important for memory and learning, including 
the prefrontal cortex (Janowsky, 2006). Brännvall et al. (2005) found that nandrolone 
inhibited the proliferation of neural stem cells and neurogenesis in the dentate gyrus in adult 
rats. These authors conclude that nandrolone may have long-term consequences on cell 
recruitment in the brain. Specifically inhibiting neurogenesis in the dentate gyrus of adult rats 
has been associated with impaired spatial and recognition memory (Jessberger et al., 2009), 
providing a possible mechanism for the impairments seen in these capacities in rats treated 
with AAS compared to vehicle. Living in an enriched environment and exercise has been 
shown to increase neurogenesis in dentate gyrus in rodents (Kempermann, Kuhn & Gage, 
1997; Brown et al. 2003; Bjørnebekk, Mathé & Brené, 2005) and improve spatial memory in 
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adult rats (Nilsson et al., 1999). A recent animal study has shown that this positive effect of 
exercise might be ameliorated by the use of AAS (Novaes Gomes et al., 2014). 
 Taken together, the few studies that have investigated the association between AAS 
use and executive functions have shown AAS to lead to neurochemical alterations in brain 
regions important for executive functions (Pieretti et al., 2012; Kurling-Kailanto, Kankaanpää 
& Seppälä, 2010). Preliminary evidence has indicated that acute AAS-intoxication may be 
associated with poorer planning and set-shifting, and an increased emotional reactivity in 
humans (Hildebrandt et al., 2014), and a decrease in behavioral flexibility in rats (Wallin & 
Wood, 2015).  
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2 Aims and hypotheses 
AAS use is widely used among the general population (Sagoe et al., 2014) and increased 
aggression is a commonly reported side effect of AAS use in both humans (e. g. Pope, Kouri 
& Hudson, 2000; Thiblin, Nyberg & Moberg, 2013) and animals (e. g. Olivares et al., 2013, 
Long et al., 1996), although the causes for this association remains largely elusive (Wood et 
al., 2013). Some evidence also indicate that AAS may have negative effects on brain 
maturation (Cunningham, Lumia & McGinnis, 2013), executive functions (Wallin & Wood, 
2015; Kanayama et al., 2013) and brain areas important for executive functions (Pieretti et al., 
2012; Kurling-Kailanto, Kankaanpää & Seppälä, 2010). The aims of this investigation are to 
elucidate the effects AAS pattern of use on aggression and executive functions. The 
hypotheses for this study are as follows: 1. Long-term AAS use is associated with increased 
levels of aggression. 2. Long-term AAS use is associated with lower levels of executive 
functions. 3. Aggression in AAS users is related to pattern of AAS use. 4. Lower levels of 
executive functions are related to pattern of use. 
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3 Methods 
3.1 Study participants 
The sample was drawn from the ongoing research project Long-term androgenic anabolic 
steroid abuse on brain structure, cognitive functioning and emotional processing coordinated 
from the Department of Physical Medicine and Rehabilitation, at the section of 
neuropsychology, Oslo University Hospital, Oslo. The participants in the study are male 
weightlifters belonging to one of the following groups: Men reporting at least one year of 
cumulative AAS use and men who have never tried AAS.  
Participants were recruited through posts on Internet forums concerning bodybuilding, 
strongman, fitness and weightlifting, and forums (open and closed) that directly target steroid 
users. Recruitment also occurred through advertising on a Facebook project page. Posters and 
flyers were distributed on selected gyms, and participants in the study were given flyers and 
encouraged to spread the word about the study to potential candidates. In order to catch the 
attention of the right people we chose the following headline on the recruitment material and 
advertisements: “Ever bench-pressed 120kg?”. In the recruitment information the study aim 
was explicitly stated. For the AAS group we sought both current and previous users having 
used AAS over time, and at least exceeding one year of cumulative use. For the control group 
we sought men who spend much time on strength training (weight lifting) with no experience 
with AAS or equivalent doping substances. The participants were compensated for their 
participation with 1000NOK (~125 USD).  
In total 159 men participated in the study divided into 87 current or past AAS users, 
and 69 non-using controls consisting of men who either were using considerable amount of 
time on weightlifting and/or who classified themselves as highly experienced power lifters 
competing at a national level. Two users did not entirely fulfill our inclusion criterion, in that 
they only had close to one year of cumulative AAS use, and one control had very little 
experience with strength exercise. They were nonetheless included in this investigation, as 
these criteria were as strict as they were because of the MR-data not included in the present 
paper. A total of 6 controls and 14 users failed to deliver their BPAQ questionnaires. The final 
sample in the analyses of differences in aggression was thus 63 controls and 73 AAS users. 
Data on the Trail Making Test and Color Word Interference Test were missing for two AAS 
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users, analyses on executive functions, then, will include 69 controls and 85 AAS users. The 
ANT was completed by 66 controls and 83 users.  
3.2 Assessment procedure 
The study evaluation included questionnaires the participant had filled out beforehand, which 
were delivered at the start of the evaluation to the investigator. Then followed an interview 
about exercise habits, medical and psychiatric disease history, use of medications (specifying 
psychotropic drugs), drug and alcohol use and other potential risk factors regarding cognition, 
such as head trauma or encephalitides. Participants belonging to the user group were 
interviewed about the nature of their AAS use. The cognitive evaluation followed after the 
interview. Lastly, the participants were given the MCMI-III (Millon, 1994) to be filled out at 
home and returned via mail. The entire assessment lasted for about three hours, with some 30 
minutes more for AAS users due to the interview regarding their AAS use and the SCID 
module on AAS-dependence.  
3.3 Interview assessment 
The interview evaluation consisted of a semi-structured interview concerning the participants’ 
exercise habits, i.e. number of weightlifting vs. endurance training sessions per week, their 
personal records in bench press, deadlift and squat, and any achievements in sports they have 
participated in. They were asked about any previous head trauma or substance abuse that 
might influence cognition. Participants in the user group were also asked about the nature of 
their AAS use, such as age of onset, number of lifetime cycles, number of years of AAS use 
and an estimation of average weekly AAS dose within cycles. They were also asked whether 
they had ceased using AAS, and if not, where in the cycle they were presently (at the time the 
assessment took place). Any medical, emotional or cognitive side effects they had 
experienced were also recorded. Then a module from SCID II (First et al., 1997), assessing 
AAS dependence (Pope, Kean et al., 2010) was administered. This module has shown 
promising psychometric properties in the preliminary study by Pope, Kean and colleagues 
(2010).  
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3.4 Estimated lifetime dosage  
Estimated lifetime doses of AAS in milligrams were calculated using the obtained 
information about AAS pattern of use (e.g. cycle duration, number of cycles, years of use, any 
cessation of use, estimated weekly dosage etc.). For most participants this was easily 
calculated as their AAS use was carefully planned for and implemented according to the plan. 
Some users, however had not equally good overview or were just not very systematic about 
their usage habits. They could have used large quantities over a long period of time, but the 
pattern of use was more guided by spontaneity or what preparations they had access to at the 
moment, rather than by a usage plan. Some reported they had use for so long that they had 
lost track of their history of use. For these participants it was harder to calculate a thought 
lifetime dose (and accordingly for a few this value is missing (n=4)). However for most we 
have made an attempt based on the available information. It is thus important to have in mind 
that this is not an exact measure, rather a rough estimate of a lifetime AAS dose. 
3.5 Previous or current drug problem 
The presence of a previous or current drug problem was determined based on some fixed 
guidelines and partly by discretionary evaluation. The following information was used; two 
scales from the MCMI-III; the drug and the alcohol dependence scales, self-reports on 
previously used substances outside medical use (e.g. ecstasy, cocaine, MDMA, Paralgin 
Forte). This form was taken from the M.I.N.I.-plus psychiatric diagnostic interview 
instrument (version 5.0; Sheehan et al., 1998). Further information was based upon reports 
about number of times used alcohol and illicit drugs the last six months on obtained from the 
ASEBA Adult Self-Reports (ASR) questionnaire. 
Of these measures the two MCMI scales were given the most weight in the 
assessment. Participants that obtained a base rate (BR) score of 75 or above (indicating the 
presence of a clinical syndrome) on one of these scaled fulfilled the criteria of having a 
“previous or current drug issue”. If participants obtained BR scores close to 75 (> 70), then 
the evaluation was guided by the self-report and the ASR information. 
The self-report schema was Taken from the M.I.N.I.-plus psychiatric diagnostic 
interview instrument (version 5.0), (evaluating substance dependence), and was administered 
during the interview. Participants were asked to mark substances they have ever used in order 
to get high, followed-up by questions to clarify whether the reported substances had been 
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used extensively or only a few times, to get an indication of the duration of use, and if the 
substances in question were still being used by the participant or not. 
Borderline cases were discussed by two investigators, and often a strict evaluation was 
preferred as it was considered to be valuable to be able to conduct analyses where concurred 
substance abuse would have minimal influence on the findings. 
3.6 Executive functions 
Executive functions were assessed using the Color Word Interference Test (CWIT) and Trail 
Making Test (TMT) from the D-Kefs battery (Delis, Kaplan & Kramer, 2001), as well as the 
Attention Network Test (ANT, Fan et al., 2002).  
In the CWIT the participant is presented with a paper sheet on which the stimuli are 
printed. It consists of four conditions: In the first condition, the sheet consists of colored 
patches (red, green and blue) and the participant is instructed to say out loud the colors of the 
patches. The second condition involves reading color words (red, green and blue) written in 
black ink. In the interference condition, color words are presented written in ink of another 
color (either red, green or blue). The participant is instructed to say out loud the color of the 
ink, and override the impulse to read the word. This then, tests the participant’s ability to 
override an impulse (reading the word) to complete the task successfully, and was used as a 
measure of executive inhibition. Lastly, the fourth condition again involves color words 
written in colored ink, with some of the words printed inside rectangles. The participant is 
given the same instructions as in the third condition, with the added rule that the participant is 
to read the words placed in rectangles, regardless of the color of the ink. This test requires the 
ability to shift between different rules, and is thus a measure of cognitive flexibility. In all 
conditions, the participant is instructed to complete the task as fast as they can without 
making any errors. In addition to time taken to finish the third and fourth conditions, the total 
number of errors committed on these conditions was also included as a measure of inhibition 
(MacLeod, 1991). Errors were recorded when the participant read the word instead of saying 
the color in the third condition, and when the participant read the words outside rectangles or 
said the color of the word inside rectangles on the fourth condition. Errors were recorded 
whether or not the participant immediately corrected the error. Contrast measures were 
obtained by subtracting the scores on CWIT 1 and 2 from the results on CWIT 3, in order to 
remove the effect of processing speed on this measure (Delis, Kaplan & Kramer, 2001). This 
created two new variables of inhibition; CWIT3-1 and CWIT3-2. Subtracting the scores on 
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CWIT 3 from scores on CWIT 4 created a measure of cognitive flexibility removing the effect 
of processing speed and inhibition: CWIT4-3. 
Like the CWIT, the TMT has four conditions and is a pencil and paper test. In the first 
condition, numbers and letters are presented in a scrambled fashion on the paper. The 
participant is tasked with finding and crossing out all 3s. This test involves visual search and 
psychomotor speed. In the second condition, the participant is similarly presented with 
numbers and letters but asked to draw a line from number to number in a rising order, from 1 
to 16. The third condition is similar, other than the participant being tasked with drawing a 
line from letter to letter in alphabetical order. This are tests of psychomotoric speed. On the 
fourth condition the participant is instructed to draw a line like in the previous two conditions, 
but this time the line is to be drawn alternating between number and letter (1-a-2-b etc.). This 
is a measure of cognitive flexibility as it involves shifting attention as well as cognitive rules. 
Contrast measures were obtained in a similar fashion as for the CWIT; by subtracting the 
scores on TMT 3 and 2 from the scores on TMT 4 in order to remove the effect of 
psychomotoric speed on this measure, creating two new variables: TMT4-2 and TMT4-3.  
Another measure of executive functioning was the conflict-condition on the Attention 
Network Test (ANT, Fan et al., 2002). The ANT is a reaction time test designed to measure 
three aspects of attention: Alerting; maintained vigilant attention, Orienting; selection of and 
orienting toward sensory information and Executive control; the process of resolving 
incongruent stimuli (Westlye et al., 2011). In the ANT, the participant is asked to fixate on a 
contrally located cross on a computer screen. The stimuli consist of five arrows presented 
either immediately above or immediately below the fixation point. The participant’s task is to 
indicate whether the middle arrow points to the left or to the right by pressing one of two 
buttons. The stimuli may be congruent; all the arrows point in the same direction, or 
incongruent; the flanking arrows point in the opposite direction of the middle arrow. The 
conflict measure is computed by subtracting the median reaction time (RT) for congruent 
stimuli from the median RT for incongruent stimuli, and then dividing the difference by the 
median RT of the congruent stimuli. This score is a measure of executive control, as it 
pertains to the ability to resolve cognitively incongruent stimuli and disregarding distracting 
stimuli (Westlye et al., 2011).  
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3.7 Aggression 
Aggression was assessed using the Buss Perry Aggression Questionnaire (BPAQ, Buss & 
Perry, 1992). This is a 29-item questionnaire that produces four subscales and an additional 
total aggression scale. The subscales are ”physical aggression”, ”verbal aggression”, ”anger” 
and ”hostility”, as well as ”total aggression”; the sum of the scores on the four subscales. 
These four factors have been replicated through factor analysis in several languages (Vigil-
Colet et al., 2005). The physical and verbal aggression subscales represent the behavioral 
manifestations of aggression in the BPAQ, in that they assess the degree to which the 
participant tends to use or is willing to use aggressive behavior within the physical or verbal 
domain. The anger subscale assesses the participant’s physiological arousal and preparedness 
to experience aggression (Buss & Perry, 1992). Anger has been conceptualized as a trait, and 
defined as “the disposition to perceive a wide range of situations as annoying or frustrating 
and by the tendency to respond to such situations with elevations in state anger” (Spielberger, 
1999, cited in Owen, 2011). The hostility scale assesses the participant’s feelings and 
thoughts of rancor and malice, thus pertaining to cognitions regarding aggression (Buss & 
Perry, 1992).  
3.8 Pattern of use 
In addition to the estimated lifetime dose and AAS-dependency, total number of years used 
and debut age were used as measures of pattern of AAS use, based on self-reports. The 
calculation of estimated lifetime dose is detailed above. Debut age was recorded as the 
participant’s age at first exposure to AAS. Total number of accumulated years used is the total 
number of years the participant considered himself an AAS user, including periods between 
AAS cycles. Participants were categorized into one of three groups regarding total years of 
cumulative use; Short- (1-4.99 years, N=19), medium- (5-9.99 years, N=34) and long- (≥10 
years, N=34) term use. Note that “long-term” is here used in a relative fashion, as all 
participants in the AAS sample could be described as having a long-term AAS career (more 
than one year). 
3.9 Statistical analyses 
All analyses were performed using SPSS version 22. Assumptions were checked before using 
parametric tests in analyses. Normality was checked using Shapiro-Wilk Test and 
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Kolmogorov-Smirnov Test. Considering the present investigations rather large sample size, 
we also checked distributions using histograms on variables whose tests of non-normality 
were significant (Field, 2009). Assumptions about homogeneity of variance were assessed 
using Levene’s Test for homogeneity of variance. Missing values for questionnaire variables 
were replaced by predicted values using the expectation-maximization method (Howell, 
2007) after checking the assumption that they were missing in a random order, using Little’s 
Missing Completely At Random-test (Little’s MCAR test; Little, 1998).  
Main effects of group on BPAQ-scores were first tested using general linear modeling, 
with group as fixed factor and age as covariate. The same analyses were used when testing 
main effects on neuropsychological test scores, also including education level as a covariate, 
as these are known correlates across a range of cognitive functions (Lezak et al., 2012). For 
the ANT scores, no covariates were included, as these were T-scores. The variables of errors 
committed on CWIT 3 and 4 were heavily skewed toward few or no errors. Group differences 
on this measurement will thus be analyzed using Mann-Whitney’s U test. These analyses did 
not include age as a covariate, as there age effects on number of errors committed on the 
CWIT are small in the age group under investigation here (Delis, Kaplan & Kramer, 2001). 
On all measures of executive functioning, we did separate analyses for a subsample of 
participants with and without previous or current drug problem, as use of a range of illicit 
substances is a known risk factor for impaired cognitive functioning (Lezak et al., 2012). 
Differences on important demographic variables were assessed using Student’s T-test, and 
when assumptions about normality did not hold, Mann-Whitney U. In the latter case, effect 
sizes were calculated by hand (see Field, 2009). 
Correlations between AAS age of onset, estimated lifetime dose and BPAQ-scores 
were tested using Partial Correlation, controlling for age. In case of neuropsychological test 
data, education level was controlled for in addition to age. In cases were assumptions about 
normality were not fulfilled, correlations were assessed using Spearman’s Rho. As non-
parametric partial correlation is not a default option in SPSS, this was achieved using an 
edited syntax that used results from correlation analysis using Spearman’s Rho as basis for a 
new partial correlation (IBM, 2015; see appendix 3).  
Exploratory analyses were then performed to assess further the associations between 
AAS use pattern and aggression and executive functions. 
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4 Results 
4.1 Descriptive statistics 
Descriptive statistics concerning age, education level and exercise habits are presented in 
table 1. The groups did not differ significantly in age, as controls had a mean age of 31.8 
(SD=9.4) years while users had a mean age of 33.4 (SD=8.4). Controls had a mean of 15.8 
(SD=2.7) years of education while users had a mean of 14.2 (SD=2.7), which was a 
significant difference (T=3.56, p<.01). The groups were similar on all measure of exercise 
habits, except time spent strength exercising where controls spent significantly more time per 
week (t=2.96, p<.05). Controls spent 463 (SD=242) minutes per week while AAS users spent 
351 (SD=204) minutes strength exercising. AAS users reported significantly higher personal 
records on bench press (Mcon=138.5 kg, MAAS=168.4 kg, t=-6.29, p<.001), squat (Mcon=172.9 
kg, MAAS=216.4 kg, t=-4.98, p<.001) and deadlift (Mcon=199.6 kg, MAAS=216.4 kg, t=-3.80, 
p<.001).  
Controls reported consuming a mean of 3.25 (SD=4.75) units of alcohol per week, 
while users reported a mean of 1.63 (SD=3.12) units per week, which was a significant 
difference (t=2.53, p<.05). A total of 64 (92.8%) of controls were classified as not having a 
previous or current drug problem, while 4 (5.8%) were. In the user group, 52 (59.1%) were 
classified as not having a previous or current drug use, while 35 (39.8%) were. A Chi-square 
test revealed a significant association between group and being classified as having a previous 
or current drug problem (X
2
 (df=1, N=155) = 23.91, p<.01), with significantly more users 
being classified as having a previous or current drug problem.
 
Accordingly, this will be taken 
into account in the statistical analysis concerning aggression and executive functions. 
 Concerning the nature of AAS use in the user group, 30 (34.5%) of the users reported 
having ceased using AAS, while 54 (62.1%) reported to still be active AAS users. Mean debut 
age of AAS use was 22.14 (6.54) years, ranging from 12 to 52 years. The mean estimated 
lifetime dosage was 368 364.40 (SD=523 510.15) mg, ranging from 15000.00 mg to 
3 969 375.00 mg. The mean number of total years of AAS use was 9.13 (5.68) years, ranging 
from 1 to 30 years.  
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4.2 Executive functions 
4.2.1 Cognitive flexibility 
On the CWIT 4 controls used on average 55.9 (SD=12.7) seconds to finish the fourth 
condition on the CWIT 4 task, while users required on average 63.7 (SD=19.1) seconds to 
finish. This difference tended toward significance (F(1,150)=3.06, p=.08). On the TMT 4, 
controls used on average 66.3 (SD=20.1) seconds while AAS users used 81.4 (SD=30.4) 
seconds. This difference was significant (F(1,150)=6.77, p<.05) with a small effect size (
=.04). Concerning the contrast measures, controls and AAS users did not differ on the CWIT4-
3 (Mcon=4.01 (10.01), MAAS=4.94 (15.97), F(1,136)=.26, p=.61). Neither did they differ on the 
TMT4-2 (Mcon=40.52 (19.67), MAAS=48.97 (27.79), F(1,136)=1.92, p=.17) or the TMT4-3 
(Mcon=39.56 (20.46), MAAS=47.97 (26.86), F(1,136)=1.92, p=.17).  
Further analyses including a subsample of only controls (N=64) and users (N=50) 
without a previous or current drug problem, a significant difference was found on the TMT 4 
(Mcon=66.92, MAAS=80.57, F(1,110)=5.75, p<.05) with a small effect size ( =.05). The 
difference between controls and AAS users in this subsample was not significant for the 
CWIT 4 (Mcon=55.72 (12.92) seconds, MAAS=63.08 (18.81), F(1,110)=1.77, p=.19). These 
groups did not differ significantly on either of the contrast measures of cognitive flexibility. 
4.2.2 Inhibitory control 
Controls used on average 52.1 (SD=11.8) seconds while AAS users used on average 58.4 
(SD=15.8) seconds to finish CWIT 3. This difference was statistically significant 
(F(1,150)=4.45, p<.05) with a small effect size ( =.03). On CWIT 3, controls committed on 
average 0.80 errors while users committed on average 1.25 errors. This difference was 
significant (z=-2.31, p<.05) with a small effect size (r=.19). On CWIT 4, controls committed 
on average 1.1 (SD=1.6) errors, while users committed 1.8 (SD=2.0), resulting in a significant 
difference (z=-3.20, p<.01) with a medium effect size (r=.26). The groups did not differ 
significantly on the contrast measures, but these differences tended toward significance: 
CWIT3-1 (Mcon =21.97 (8.83), MAAS=26.12 (13.43), F(1,148)=2.73, p=.10); CWIT3-2 (Mcon 
=30.61 (10.01), MAAS=35.40 (14.45), F(1,148)=3.21, p=.07).  
When investigating a subsample consisting of only controls (N=64) and users (N=50) 
without a previous or current drug problem, the groups still differed significantly on CWIT 3 
(Mcon=51.53 (10.39) seconds, MAAS=58.14 (15.34) seconds, F(1,110)=4.42, p<.05) with a 
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small effect size ( =.04). These groups also differed on the contrast measures CWIT3-1 
(Mcon=21.31 (6.99), MAAS=25.94 (12.49), F(1,110)=4.34, p<.05, =.04) and CWIT3-2 
(Mcon=30.10 (8.33), MAAS=35.27 (13.06), F(1,110)=4.41, p<.05, =.04) (see fig. 1). 
Controls in this subsample also displayed significantly fewer errors committed on CWIT 3 
(Mcon=.73 (SD=1.06) errors, MAAS=1.18 (SD=1.19) errors, z=-2.26, p<.05) and CWIT 4 
(Mcon=1.13 (SD=1.59) errors, MAAS=1.88 (SD=2.17) errors, z=-2.38, p<.05), with medium 
effect sizes (CWIT 3 errors: r=.21; CWIT 4 errors: r=.22).  
4.2.3 Executive control 
On the conflict condition of the ANT, controls acquired a mean T-score of 8.81 (SD=2.57) 
while users had a mean T-score of 7.64 (SD=2.69). This difference was significant 
(F(1,147)=7.31, p<.001) with a small effect size ( =.05). Mean scores for these groups are 
presented in fig. 2. 
When investigating a subsample consisting of only controls (N=64) and users (N=50) 
without a previous or current drug problem, a significant difference still emerged on the 
Conflict-condition of the ANT (Mcon=8.84 (SD=2.49), MAAS=7.67 (SD=2.36), F(1,110)=6.40, 
p<.05) with a small effect size ( =.06). 
4.2.4 Pattern of use 
When comparing a subsample of AAS users with 10 or more years of total AAS use (N=33) 
to controls (N=69), significant differences still emerged on the CWIT3-1 (Mcon=21.97 (8.83), 
MAAS=28.67 (16.80), F(1,98)=4.10, p<.05, =.04) and CWIT3-2 (Mcon =30.61 (10.01), 
MAAS=38.89 (16.94), F(1,98)=6.76, p<.05, =.06). Both effect sizes were small. Scores on 
these measures were not related to any other measures of pattern of use.  
 
4.2.5 Self-reported side effects 
A total of 16 (18.8 %) of AAS users included in analyses of executive functions reported 
experiencing either “being impulsive” or “poorer impulse control” as a side effect of AAS 
use. Further, 3 (3.5 %) AAS users reported problems with concentration associated with AAS 
use. Thus, 19 (22.3 %) of AAS users reported side effects that may be related to executive 
functions. 
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4.3 Aggression 
4.3.1 Group differences 
There were significant group differences on the total aggression scale and nearly all subscales 
of the BPAQ. These results are presented in table 2 and fig. 3. On the Total Aggression Scale, 
controls acquired a mean score of 73.11 (SD=19.85) compared to 97.28 (SD=30.11) in the 
user group. This was a significant difference (F(1,133) = 31.24, p<.001) with a strong effect 
size ( =.19). Following are the mean scores on the subscales for controls and AAS users 
respectively: 21.80 (SD=8.64) versus 33.57 (SD=12.82) on physical aggression (F(1,133) = 
39.62, p<.001, =.23); 18.40 (SD=5.48) versus 20.12 (SD=6.34) on Verbal aggression, a 
significance which only tended toward significance (F(1,133)=3.34, p=.07); 15.77 (SD=6.35) 
versus 22.00 (SD=9.50) on Anger (F(1,133) = 20.25, p<.001, =.13); and 17.14 (SD=7.47) 
versus 21.59 (SD=9.05) on Hostility (F(1,133) = 10.06, p<.01, =.07). Effect sizes ranged 
from small (Hostility) to moderate (anger) and strong (Total Aggression, Physical 
Aggression) 
 When comparing AAS users that had ceased using and active users, statistically 
significant differences emerged on the anger, hostility and total aggression scales of the 
BPAQ: Anger (Mceased=25.35, Mactive=20.20, F(1,68)=4.61, p<.05, =.06), hostility 
(Mceased=25.05, Mactive=19.67, F(1,68)=5.99, p<.05, =.08), and total aggression 
(Mceased=106.76, Mactive=91.95, F(1,68)=3.84, p<.05, =.05). All these effect sizes were 
small. 
4.3.2 Aggression in AAS users without concurrent drug use 
When excluding participants with a current or previous drug problem, the remaining 
subsample of AAS users (N=44) still displayed higher scores than controls (N=58). Following 
are the mean scores for controls and users respectively for the subscales: 21.11 (SD=8.08) 
versus 30.08 (SD=11.85) on physical aggression (F(1,99) = 21.13, p<.001, =,18); 18.26 
(SD=5.56) versus 19.34 (SD=6.28) on verbal aggression (F(1,99)=1.13, p=.291); 15.47 
(SD=6.39) versus 19.52 (SD=8.45) on Anger (F(1,99) = 7.86, p<.01, =.07); 16.74 
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(SD=6.90) versus 19.78 (SD=7.56) on Hostility (F(1,99) = 4.69, p<.05, =.05); and 71.58 
(SD=18.21) versus 88.72 (SD=27.95) on Total Aggression (F(1,99) = 14.80, p<.001, 
=.13). Thus, when comparing controls and AAS users without a previous or current drug 
problem, there were still significant main effects of group and small (Anger, Hostility) to 
medium (Physical Aggression, Total Aggression) effect sizes on all subscales of the BPAQ, 
except the Verbal Aggression subscale.  
 When comparing AAS users without a previous or current drug problem (N=44) to 
AAS users with (N=29), significant differences emerged on the Total Aggression scale and all 
subscales, except Verbal Aggression. Means and SDs for this subsample are presented in 
table 3. For Total Aggression AAS users without a previous or current drug problem obtained 
a mean score of 88.72 (SD=27.95) versus 110.27 (SD=29.00) for users with a previous or 
current drug problem, a significant difference (F(1,70)=9.84, p<.01, =.12). Following are 
mean scores on the subscales for AAS users without and with a previous or current drug 
problem respectively: 30.08 (SD=11.85) versus 38.86 (SD=12.60) on Physical Aggression 
(F(1,70)=8.89, p<.01, =.11); 19.34 (SD=6.28) versus 21.31 (SD=6.35) on Verbal 
Aggression (F(1,70)=1.61, p=.21); 19.52 (SD=8.45) versus 25.75 (SD=9.90) on Anger 
(F(1,70)=8.07, p<.01, =.10); and lastly 19.78 (SD=7.56) versus 24.34 (SD=10.49) on 
Hostility (F(1,70)=4.56, p<.05, =.06). In these comparisons effect sizes were small 
(Hostility) to moderate (Physical Aggression, Anger and Total Aggression). Mean scores for 
controls, AAS users without and AAS users with a previous or current drug problem are 
presented in fig. 4. 
3.3.3 Pattern of AAS use: 
Using Spearman’s Rho, controlling for age, estimated lifetime dose correlated significantly 
with the physical aggression subscale (N=67, r=.28, p<.05), the anger subscale (r=.38, p<.01) 
and the total aggression scale (r=.32, p<.01). The correlations were all positive, indicating that 
a higher estimated lifetime dose was associated with higher scores on different aggression 
scales. The relationship between estimated lifetime dose and scores on the Physical 
Aggression subscale is presented in a scatter plot in fig. 5. 
Considering total duration of AAS use in relation to aggression measures, there were 
significant differences between short- (N=15), medium- (N=29) and long-term (N=29) AAS 
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users. Anger (F(2,69) = 5.12, p<.01, =0.13), Hostility (F(2,69) = 7.75, p<.01, =.18) and 
Total Aggression (F(2,69) = 4.61, p<.05, =.12) showed a significant main effect of use 
duration. This effect was not significant for Physical Aggression (F(2,69)=1.94, p=.15). Mean 
scores for the duration groups and controls are shown in Fig. 6. 
AAS users that fulfilled the SCID-criteria of an AAS dependency syndrome scored 
higher on the BPAQ compared to AAS users that did not fulfill these criteria. A main effect of 
AAS dependency was found on several subscales of the BPAQ. Following are the mean 
scores for non-dependent and dependent AAS users respectively: 28.85 (SD=11.60) versus 
37.92 (SD=12.47) on Physical Aggression (F(1,70)=9.71, p<.01, =.12); 18.46 (SD=9.08) 
versus 25.26 (SD=8.76) on Anger (F(1,70)=9.95, p<.01, =.12); 19.06 (SD=7.10) versus 
23.92 (SD=10.07) on Hostility (F(1,70)=5.39, p<.05, =.07); and 85.28 (SD=25.96) versus 
108.34 (SD=29.71) on Total Aggression (F(1,70)=11.68, p<.01, =.14).  
4.3.4 Age of onset 
In correlational analyses involving age of AAS onset, we used Spearman’s Rho controlling 
for age, as the age of onset-variable was highly leptokurtic and skewed toward adolescence. 
These analyses included 70 AAS users. Age of onset of AAS use was negatively correlated 
with two subscales, as well as the total aggression scale on the BPAQ: Physical Aggression 
(rs=-.28, p<.05), Anger (rs=-.28, p<.05) and Total Aggression (rs=-.29, p<.05). All of these 
correlations were weak. Negative correlations indicate that a higher debut age was associated 
with lower scores on the Physical aggression and Anger subscales, as well as the Total 
aggression scale.  
4.3.5 Self-reported side effects 
Of the 73 AAS users who turned in their BPAQ, a total of 31 (42.5 %) reported experiencing 
“aggression” as a side effect of AAS use. An additional 6 (8.2 %) users reported “short fuse”, 
6 (8.2 %) users reported “irritability” and 5 (6.8 %) reported “mood swings” without 
mentioning aggression. Thus, a total of 48 (65.8 %) of the AAS users reported aggression or 
mood related side effects (see fig. 7). 
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4.6 Aggression and Executive functions 
Inhibition, as measured by the contrast measures of the CWIT, correlated significantly with 
the Total Aggression Scale of the BPAQ: CWIT3-1 (r=.17, p<.05); CWIT3-2 (r=17, p<.05). The 
contrast measure of the CWIT did not correlate significantly with any of the subscales, 
however. No other measures of executive functions correlated with measures of aggression. 
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5 Discussion 
The principal findings from the present investigation were that AAS users performed worse 
than non-AAS using controls on measures of executive inhibition and executive control, and 
that AAS users achieved higher scores than controls on self-report measures of aggression. 
Furthermore, higher levels of aggression were associated with a combination of AAS and a 
previous or current drug problem, fulfilling the criteria for AAS dependency, having a longer 
duration of AAS use, higher estimated lifetime dosages and lower age of onset.  
As in numerous previous studies, the sample in this investigation presented with a 
significantly higher prevalence of drug abuse among AAS users. The reasons behind the high 
prevalence of concomitant drug use in AAS users have been hotly debated. A general pattern 
of risk-taking behavior thought to predispose individuals to both experimenting with AAS and 
other drugs of abuse has been proposed as one explanation (Pallesen et al., 2006; Williamson 
& Young, 1992). Some evidence also indicates that AAS might lead to neurochemical 
alterations that can predispose AAS users to use of other illicit drugs of abuse. Rats treated 
with AAS (nandrolone) self-administer significantly more alcohol than vehicle treated rats 
(Johansson et al., 2000). Indeed, there is a growing literature on the effects of AAS on the 
opioid system, indicating that use of AAS may alter this system to increase vulnerability for 
opioid dependence in AAS users (Nyberg & Hallberg, 2012). The lower levels of inhibition 
and executive control displayed by AAS users in the present investigation may also provide 
one other mechanism behind this association as low inhibition has been shown to be a risk 
factor for abuse of a range of recreational drugs (Jentsch & Pennington, 2014). This may 
increase the prevalence of use of other illegal substances either through a common 
predisposing factor or a negative side effect induced by AAS use, or both.  
5.1 Executive functions 
The finding that AAS users report higher levels of aggression than controls was expected on 
account of the abundance of research on this association. However, this is to the best of our 
knowledge the first time that long-term use of AAS in humans has been associated with lower 
levels of executive inhibition and executive control compared to non-AAS using controls. We 
have found in a large sample of previous and current AAS users without a history of drug 
abuse, that long-term AAS use is associated with lower levels of executive inhibition and 
executive control. This finding confirmed our hypothesis that AAS users would display lower 
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levels of executive functions compared to controls. It also supports the few animal studies on 
AAS use and executive functions in rats, which have found AAS to lead to alterations in the 
prefrontal cortical-striatal circuitry important for executive functions (Wood et al., 2013). 
Findings on executive functions were not uniform however. When including the entire 
sample, AAS users performed significantly worse than controls on executive control. 
Concerning executive inhibition, AAS users performed significantly more errors on the third 
and fourth conditions of the CWIT, but the contrast measures only tended toward 
significance. Self-reports concerning side effects of AAS use also support the finding that 
AAS users perform somewhat poorer on measures of inhibition, as 16 (18.8 %) of AAS users 
reported diminished impulse control as a negative side effect of AAS use. While a main effect 
of group appeared on the TMT 4, the contrast measures of TMT4-3 and TMT4-2 did not reveal 
significant differences between AAS users and controls. Thus, the significant difference on 
the TMT 4 likely reflects a poorer psychomotoric speed in AAS users compared to controls 
rather than an impaired capacity for cognitive flexibility. The contrast measure CWIT4-3 also 
revealed no difference between controls and AAS users.  
As noted, many AAS users had a previous or current drug problem. Abuse of a range 
of psychostimulants has been associated with impairments in several cognitive domains 
(Wood et al., 2014). Cocaine, for example, has been associated with impairments in 
psychomotoric speed (Beatty et al., 1995) and executive functions (Beveridge et al., 2008; 
Kalapatapu et al., 2011). A similar pattern has been shown for amphetamine (Scott et al., 
2007). The high prevalence of use of such illicit drugs of abuse in the user group warranted 
separate analyses and considerations for AAS users without use of these other substances. 
When conducting separate analyses for AAS users without a previous or current drug 
problem, a somewhat different pattern emerged for neuropsychological test results of 
executive functions.  
Concerning executive inhibition, controls and AAS users without a previous or current 
drug problem differed significantly on the CWIT3-1 and CWIT3-2, with these AAS users 
performing significantly worse than controls. Users in this subsample also made significantly 
more errors on both CWIT 3 and 4. Thus, AAS users with no history of drug abuse performed 
worse than controls on all four measures of executive inhibition. The conflict condition of the 
ANT also revealed a significant difference between AAS users and controls, with controls 
achieving significantly higher T-scores. These findings indicate that AAS users have a lower 
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capacity to override impulses by using top-down executive functions and are slower at 
resolving conflicting stimuli compared to non-AAS using controls. 
One somewhat unexpected finding was that the difference between AAS users and 
controls on the contrast measures of inhibition only tended toward significance when 
including participants with a previous or current drug problem. This may be explained by the 
inclusion of controls with a previous or current drug problem (N=4), who obtained 
significantly worse mean scores than controls and both groups of AAS users on the two 
contrast measures on inhibition. AAS users with a history of drug abuse performed no 
different than AAS users without (see fig. 8).  
Controls and AAS users did not differ on any measure of cognitive flexibility. This 
somewhat contradicts the finding from one study that found decreased levels of behavioral 
flexibility in rats treated with AAS (Wallin & Wood, 2015). The cause behind this 
discrepancy may stem from the way flexibility was assessed. The CWIT 4 and TMT4 assess 
relatively restricted subcomponents of flexibility: The CWIT 4 assesses flexibility by 
requiring the participant to shift cognitive rule sets, while the TMT4 assesses flexibility by 
requiring the participant to shift back and forth between two different classes of stimuli, and is 
important for higher level tasks such as multi-tasking and divided attention (Delis, Kaplan & 
Kramer, 2001). Wallin and Wood (2015) used a rule-reversal paradigm, requiring the 
participant to “unlearn” learned rules to continue succeeding in a task. This could be 
conceptualized as a more global test of flexibility, comparable to the Wisconsin Card Sorting 
Test (Lezak et al., 2012) in humans, which was not included in the present study.  
The lower levels of executive inhibition and executive control seen in AAS users may 
be attributed to a neurotoxic effect of AAS. As has been described earlier, AAS has been 
shown to lead to alterations in dopamine functioning in the prefrontal cortical-striatal circuitry 
(Wood et al., 2013; Kurling-Kailanto, Kankaanpää & Seppälä, 2010) and alterations in brain 
nerve growth factor in the basal forebrain of rats (Pieretti et al., 2012). The prefrontal cortical-
striatal circuitry is important for executive functions, such as behavioral flexibility (Wallin & 
Wood, 2015) and risk-reward decision making (Simon et al., 2011). The finding that AAS 
users without a previous or current drug problem performed worse than controls on measures 
of executive inhibition and executive control, and the findings from animal models, indicates 
that the lower levels of executive inhibition and executive control in the AAS users may not 
be attributable to the high prevalence of concomitant drug use in this group. 
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 Aside from the possibly neurotoxic effect of AAS, another explanation behind the 
lower scores of executive functions in AAS users is that lower levels of executive functioning 
might be a risk factor for AAS use. While this possibility has not been explicitly investigated 
for AAS use, poor inhibition and impulsiveness has been identified as a risk factor for use of a 
range of other illicit substances (Jentsch & Pennington, 2014). For example, longitudinal 
studies have shown poor inhibition in childhood to be related to a higher risk for alcohol 
dependency and use of illicit substances later in life (Caspi et al., 1996; Tarter et al., 2003). 
Hypothetically, individuals with a lower level of inhibition initially, might be more prone to 
yield to the tempting fast route offered by AAS and less capable at ceasing AAS use in face of 
negative side effects. Lower executive functioning prior to AAS use would lend support to the 
risk taking behavior-hypothesis, which has been put forward as one explanation of the high 
prevalence of concurrent drug use in AAS users (van Amsterdam, Opperhuizen & Hartgens, 
2011).  
In addition to a direct causal neurotoxic effect and lower executive functions as a risk 
factor for AAS use, some of the medical conditions associated with AAS use can be thought 
to impact executive functions. AAS use has been associated with a multitude of medical 
conditions (Golestani et al., 2011). Several studies have found increased prevalence of 
hypertension in AAS users compared to controls in the absence of other known risk factors 
(Hartgens & Kuipers, 2004; Achar et al. 2010; van Amsterdam, Opperhuizen & Hartgens, 
2011; but see Edvardsson, 2014). Hypertension is of course a risk factor for cognitive 
impairment through the significantly elevated risk for vascular accidents (Lezak et al., 2012), 
but in the current study, these such participants would be excluded. Hypertension unrelated to 
stroke is on the other hand an established risk factor for cognitive impairment, possibly 
through increased occurrence of covert vascular brain injury (Tzourio, Laurent & Debette, 
2014). Across cognitive domains, especially executive functions and processing speed have 
been shown to be more susceptible to decline due to hypertension than other cognitive 
abilities (Debette et al., 2011). As we did not collect data on the AAS users’ blood pressure, 
this is a possibility that deserves further investigation.  
Recurrent periods of hypogonadism after AAS cycles may also constitute a risk factor 
for cognitive decline. Hypogonadism has been associated with lowered levels of cognitive 
functioning in old men (Beauchet, 2006) and patients following traumatic brain injury 
(Wagner et al., 2012). Testosterone binds to the androgen receptors, which are widely 
distributed throughout the brain (Cherrier, 2009), and one might hypothesize that the tides of 
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exogenous androgens and aromatized estrogens that flood and drain these areas within and 
between cycles may be a possible mechanism behind cognitive decline in long-term AAS 
users.  
We thus have three probable mechanisms behind the lower scores on measures of 
executive functions in AAS users: (1) A neurotoxic effect of AAS, (2) poorer inhibition prior 
to debut as a risk factor for AAS use and (3) through a variety of medical conditions 
associated with AAS use, such as hypertension and hypogonadism. These hypotheses are not 
mutually exclusive, of course. They may all be true, so that individuals with a lower baseline 
executive functioning may experience a further decline as a consequence of long-term AAS 
use. A similar pattern has been observed in individuals with addiction to other illicit 
substances, with a low inhibition initially exacerbated by drug use (Jentsch & Pennington, 
2014). The finding that AAS users without a history of drug use still performed worse than 
controls may lend support to the hypothesis that AAS has a neurotoxic effect on the human 
brain, leading to lower levels of executive control and executive inhibition. While a smaller 
sample (N=33) of AAS users with a very long use duration (10 years or more) still displayed 
lower levels of inhibition than controls may lend support to the notion that use duration can 
influence level of executive inhibition in AAS users, levels of executive functioning were not 
related to any other measure of usage pattern. However, while we failed to find a dose-
dependent relationship between AAS use and cognitive symptoms, such a relationship was 
reported in the study by Kanayama and colleagues (2013).  
While poorer executive functions as a risk factor for AAS use may be one of the 
explanations behind this finding, one factor may have led us to underestimate this effect. The 
group of long-term AAS users is heterogeneous. While use of AAS has consistently been 
associated with use of other illicit substances and criminality, many AAS users do not engage 
in any of these behaviors. The study of 1,955 AAS users by Cohen and colleagues (2007) 
concluded that the average AAS user is highly educated, earns an above average wage and is 
motivated by the desire for increased physical strength and attractiveness. A majority of these 
users reported following strict dietary plans, and planning their AAS cycles minutely. These 
patterns of use would conceivably require higher levels of executive functions, such as 
inhibition in order to stick to these dietary regimens. As such, these individuals could be 
thought to have a high level of executive functioning initially that would limit our finding of 
AAS induced effects on executive inhibition and control. We did not identify AAS users 
belonging to this group in our study. Additionally, many of the users in our sample reported 
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following strict plans and to use AAS in a goal-directed fashion, while others did not. This 
may be one of the explanations behind the relatively weak effects of AAS on executive 
inhibition seen in the present sample. 
While this investigation showed AAS users to perform worse than controls on several 
measures of executive inhibition and executive control, the choice of control group might not 
be the most appropriate for this kind of comparison. Our control group consisted of 
recreational sportspeople who frequently lift weights. Physical exercise has previously been 
shown to improve cognition and executive functions in normal populations (Guiney & 
Machado, 2012; Colcombe & Kramer, 2003). Animal models have linked exercise with 
increased neurogenesis in the dentate gyrus of rodents (Farmer et al. 2004, Praag, 
Kempermann & Gage, 1999), providing a possible mechanism for the improvements in 
cognition and executive functions seen in exercisers. AAS have been shown to suppress 
neurogenesis in the dentate gyrus (Brännvall et al., 2005), as well as ameliorate the positive 
effects of strength exercise on cognition trough suppression of this effect (Novaes Gomes et 
al., 2014). One possibility is that AAS users in the present sample only performed worse than 
controls because the control group had the positive effect of exercise on executive functions. 
If this is true, AAS users would not have poorer executive functioning compared to non-AAS 
using individuals without the positive effect of exercise on cognition and executive functions. 
However, AAS has not only been related to the amelioration of positive effects of exercise on 
executive functions. As mentioned above, AAS use has been associated with neurochemical 
alterations in the prefrontal cortical-striatal circuitry (Wood et al., 2013; Wallin & Wood, 
2015) and brain nerve growth factor (Pieretti et al., 2012), indicating that AAS may have a 
debilitating effect on brain areas important for executive functions, beyond mitigating the 
positive effects of exercise. In addition to this, the study by Brännvall and colleagues (2005) 
found a decrease in neurogenesis in the dentate gyrus of AAS users compared to non-
exercising controls, indicating that this effect goes beyond the removal of the positive effects 
of physical exercise.  
Taken together, the findings of the present study indicate that AAS users without a 
history of drug use perform worse than non-AAS using controls on measures of executive 
inhibition and executive control, thus confirming our hypothesis that AAS use is associated 
with lower levels of executive functions. The findings were strongest for executive control, 
followed by executive inhibition, with significant differences on the conflict measure of the 
ANT and all four measures of inhibition. In contrast to this, AAS users did not perform worse 
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than controls on measures of executive flexibility. The differences in executive functions may 
be explained by AAS use directly, through a neurotoxic effect, or indirectly, through related 
medical conditions. Alternatively, it may be explained by lower executive functioning in AAS 
users prior to AAS use, or by a combination of these pathways. Measures of executive 
functions were not associated with severity of AAS use, leading to a rejection of the 
hypothesis that levels of executive functioning were associated with aspects of AAS pattern 
of use. Further research is clearly needed to assess the degree to which impaired executive 
functions is a risk factor for AAS use and elucidate the possibly causal links between AAS 
use and lowered executive functions in humans.  
5.2 Aggression 
The other main finding from this investigation was that AAS users displayed significantly 
higher levels of physical aggression, anger and hostility on self-report measures. This 
corroborates the findings of numerous previous investigations into AAS and aggression (e. g. 
Su et al., 1993; Trenton & Currier, 2005; Pagonis et al., 2006a). Furthermore, aggression 
levels were related to several measures of pattern of use. These findings confirmed the 
hypotheses that AAS users would show higher levels of aggression and that these levels 
would be associated with a more severe pattern of use. 
One of the most salient and strong findings was the large difference between AAS 
users and controls on the measure of physical aggression. This finding also aligns well with 
previous findings from both animal studies (e. g. Salas-Ramirez, Montalto & Sisk, 2010) and 
human studies that have found AAS to be particularly characteristic of perpetrators of violent 
crimes (e. g. Beaver, Vaughn & Wright, 2008) and violent behaviors (e. g. Pope & Katz, 
1990; Trenton & Currier, 2005). These findings are especially troubling considering how 
physical violence can have far reaching consequences for the person it targets and the 
perpetrators of violence themselves, as well as substantial societal costs associated with 
violence (WHO, 2014). Physical aggression scores were positively correlated with estimated 
lifetime dose of AAS, indicating that a higher lifetime consumption of AAS substances is 
associated with higher levels of physical aggression. Furthermore, users with medium-term 
AAS use (5-10 years) achieved higher scores than users with short-term (1-5 years) use, while 
users with long-term AAS use (10+ years) achieved slightly lower scores than the medium 
term group (see fig.6). This may be a result of measurement error; however it may also be 
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explained by the relatively higher age of this group, as frequency and severity of physical 
aggression decrease with age (Sweeten, Piquero & Steinberg, 2012; Tremblay, 2014). 
The General Aggression Model (GAM; DeWall & Anderson, 2011) states that 
cognitive factors within people influence how they perceive and interpret hostile situations, 
and consequently how they react. Cognitions in this regard can include beliefs about how 
people typically respond in certain situations (such as being insulted), expectations about the 
likelihood of various outcomes or how much they believe they can respond adaptively to a 
variety of events. An important focus of the GAM is that knowledge structures such as these 
influence both early and downstream psychological processes, and that they are developed 
based on the individual’s experiences with aggressive situations. One possibility that may 
explain the increases in physical aggression in AAS users may be the development of certain 
expectations about physical aggression. One of the most commonly desired effect of AAS is 
the building of muscle mass and increase in physical strength(Cohen et al., 2007), an effect 
that has been thoroughly shown for use of AAS (Clark & Henderson, 2003; Evans, 2004; Ip et 
al., 2011). AAS users in our sample also reported significantly higher personal records in 
several strength training techniques. This increase in physical strength may over time lead to 
more successful utilization of physical aggression, i.e. more fights with an advantageous 
outcome, leading to positive expectations and beliefs about the use of physical aggression in 
goal-attainment. While one study found no increase in aggressive motivation in rats (Wood et 
al., 2013) the mechanism proposed above is a complex secondary effect that is probably 
unique to humans as animals do not hold conscious beliefs about the applicability of physical 
violence across situations. Future research should investigate the development of beliefs about 
physical aggression in long-term AAS users.  
Anger was also significantly higher in AAS users. The anger-subscale of the BPAQ 
“involves physiologic arousal and preparation for aggression, [and] represents the emotional 
or affective component of [aggressive] behavior” (Buss & Perry, 1992). Anger has been 
conceptualized as an emotion (Smith, 1994) and a trait (e. g. Owen, 2010; Finkel et al., 2012) 
in that there is evidence for individual differences in the propensity to experience anger 
(Zelenski & Larsen, 2000). A higher level of trait anger has been associated with a higher 
frequency of encounters involving physical and verbal aggression (Tafrate, Kassinove & 
Dundin, 2002). One way in which higher trait anger can predispose people to aggress, is 
through a number of cognitive biases. High trait anger has been related to selective attention 
bias, favoring hostile stimuli, possibly a slight memory bias appraising past anger-provoking 
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events as more negatively than people with low trait anger, external attribution bias and other 
reasoning biases (Owen, 2010). These cognitive biases may also be hypothesized to 
contribute to the development of beliefs about physical violence proposed above. In the I
3
-
perspective, high trait anger may influence aggression by increasing the amount of instigating 
factors, that is provocative stimuli (through external attribution bias, selective attention 
toward hostile stimuli etc.) as well as be an impelling factor because high trait anger can lead 
to increased strength of the urge to act on aggressive impulses in hostile situations (Finkel et 
al., 2012). Taken together, this finding indicates that AAS users have a higher level of trait 
anger compared to non-AAS using controls, and may be prone to the associated cognitive 
biases. Furthermore, longer duration of AAS use, higher estimated life-time dose and earlier 
debut age were associated with higher levels of anger in AAS users. High trait anger in AAS 
users may be one of the explanations behind the increased levels of physical aggression seen 
in this group in both this and previous investigations. 
A higher level of hostility was also seen in AAS users compared to controls. Higher 
hostility levels in AAS users have also been found previously (Pagonis et al., 2006a; Pagonis 
et al., 2006b; Hartgens & Kuipers, 2004). Participants in the earliest experimental study on 
AAS and aggression also showed elevated levels of hostility, although this difference only 
tended toward significance (Su et al., 1993). While there is somewhat of an overlap between 
anger and hostility, anger has been labeled an emotion (Smith, 1994), while hostility has been 
characterized as an attitudinal disposition, involving cynicism, mistrust and denigration of 
others (Miller et al., 1996; Birkley & Eckhardt, 2015). The higher scores on the hostility scale 
of the BPAQ thus may indicate that AAS users may be more cynical about their surroundings, 
and exhibit more mistrust toward other people. A higher level of hostility may impact 
frequency of physical aggression in a somewhat similar manner to anger; by increasing the 
number of situations interpreted as hostile, through both attributing ill will to other persons 
and provoking other people through denigration. In much the same way as trait anger, high 
levels of hostility may be another risk factor for physical aggression. 
While group differences were found on the measures of physical aggression, anger and 
hostility, the difference seen on the verbal aggression scale only tended toward significance. 
This is somewhat puzzling, as one would expect most hostile social interactions that 
ultimately lead to physical aggression to begin with or at least also involve some form of 
hostile verbal exchange. This finding somewhat contradicts the findings of Pope, Kouri and 
Hudson (2000), who found no effects of AAS on any scales on the BPAQ except for the 
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verbal aggression subscale. One obvious methodological difference between experimental 
studies and the present is that duration of AAS use was significantly longer in the present 
investigation. The BPAQ has been used as a measure of trait aggression (e. g. Buss & Perry, 
1992; Finkel et al., 2012). It should come as no surprise that a short term AAS career would 
lead to small or no changes on measures of aggression traits. Many items on the BPAQ 
measure beliefs about violence (e. g. “I can think of no good reason for ever hitting a person”) 
or items that require experience with behaviors that for most people do not occur very often 
(e. g. “I have threatened people I know”). As this is a self-report measure, participants with 
the knowledge that they possibly have been given AAS would conceivably not endorse these 
items if their behavior only had changed recently. To support the notion that self-report 
measures of trait aggression are not the most appropriate method in investigations of short-
term AAS use, participants in the study by Pope, Kouri and Hudson (2000) displayed 
significantly elevated levels of hostile responses on the PSAP, a behavioral paradigm 
intended to provoke aggressive behavior in the experimental situation. 
As mentioned, many measures of severity of use correlated with higher levels of 
aggression. AAS users with a previous or current drug problem achieved significantly higher 
scores of aggression than AAS users without a history of drug abuse, who in turn achieved 
higher scores than controls (see fig. 4). As can be seen, AAS users without a previous or 
current drug problem are situated around the middle between controls and AAS users with a 
previous or current drug problem on all scales on the BPAQ.  
The effects of combining AAS use with use of other illegal substances have been 
investigated in animals (Long et al., 1996; Steensland et al., 2005). These investigations also 
found that combining AAS with another illicit drug lead to higher levels of aggression than 
either substance alone. As can be surmised from previous studies and the results in the present 
study, there seems to be an additive or synergistic relationship between AAS use and use of 
other drugs of abuse on levels of self-reported aggression. While the relatively higher levels 
of aggression in AAS users with a previous or current drug problem mirrored that found in 
animal models (Long et al., 1996; Steensland et al., 2005), the mechanisms behind this 
relationship in humans probably extend beyond the neurochemical synergism proposed in 
animal models.  
Involvement in drugs necessarily involves interaction with a criminal subculture of 
drug dealers and users. AAS users with a concomitant drug problem have reported other 
motives than increasing muscle mass for using AAS in other investigations, such as to 
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increase the intimidating qualities in order to avoid being taken advantage of and enabling the 
individual to take advantage of others (Cornford, Kean & Nash, 2014). Pope and colleagues 
(1996) interviewed a 27 year old man involved with drug dealing that partly used AAS in 
order to gain the confidence needed to deal drugs. Being part of a subculture like this might 
lead to higher levels of aggression as an adaptive response to the risk of being targeted by 
physical violence. Additionally, substance abuse use is closely associated with a wide range 
of psychopathology (e. g. Najt, Fusar-Poli & Brambilla, 2011).  
The higher levels of aggression seen in AAS users without drug use, however, cannot 
readily be explained by the affiliation with a criminal subculture of illegal drug use or other 
psychological problems associated with drug abuse. This is interesting, as one explanation for 
the high levels of aggression in AAS users that has been proposed is the high prevalence of 
drug use in this group (Lundholm et al., 2014; van Amsterdam, Opperhuizen & Hartgens, 
2011). The finding that AAS users without any history of drug abuse still display significantly 
higher levels of aggression than non-AAS using controls may lend support to the notion that 
this difference may be explained by the use of AAS in itself. 
Estimated lifetime dose correlated significantly with anger and physical aggression. A 
dose-dependent relationship between AAS and levels of aggression has been found in the 
experimental studies investigating short term AAS use mentioned above (Pope, Kouri & 
Hudson, 2000; Su et al., 1993), but the results from the present study reveals a dose-
dependent relationship between lifetime dose of AAS and several measures of aggression. 
One earlier investigation reported that “heavy” users suffer more severe psychiatric side 
effects, including aggression, than “light” users (Pagonis et al., 2006a). In this study, 
however, categorization within the three severity-groups depended not only on an estimated 
lifetime dose, but number of AAS-cycles completed, the number of different AAS-substances 
abused etc. The finding that estimated lifetime dose significantly correlated with aggression 
levels in AAS users may also lend support to the notion that higher consumption of AAS 
leads to higher levels of aggression. Duration of AAS use also showed an effect on several 
measures of aggression (see fig. 6). These two measures overlap somewhat, however, as 
duration of use was one of the factors taken into account when calculating estimated lifetime 
dose. Taken together, both these findings indicate that a more severe AAS using career is 
associated with higher levels of aggression compared to AAS careers involving less AAS 
consumption and shorter total use duration. 
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AAS users fulfilling the SCID-criteria for AAS dependency displayed higher levels of 
aggression compared to non-dependent AAS users. AAS dependent individuals reported 
significantly higher levels of physical aggression, anger and hostility than non-dependent 
AAS users. This finding may be a part of the general pattern that more severe use is 
associated with higher levels of aggression. A larger portion of AAS-dependent individuals 
were also classified as having a previous or current drug problem. An investigation directly 
comparing dependent and non-dependent AAS users also found AAS dependence to be 
related to comorbid psychopathology, a history of conduct disorder and opioid abuse or 
dependence (Kanayama, Hudson & Pope, 2009). These factors might form part of the 
explanation behind the higher levels of aggression see in AAS dependent individuals.  
Considering the causal mechanisms behind the higher levels of aggression seen in 
AAS users, one explanation may be neurochemical alterations induced by AAS. As noted, use 
AAS has been associated with a range of neurochemical alterations in several brain regions 
implicated in aggression and the regulation of emotion in animal models (e. g. Henderson et 
al., 2006; Penatti, Porter & Henderson, 2009; DeLeon, Grimes & Melloni, 2002; Abdelgadir 
et al., 1999). The findings from the present study, when taken together, could be seen to lend 
support to the notion that AAS use induces higher levels of aggression. Firstly, estimated 
lifetime dose correlated significantly with levels of physical aggression and anger, as well as 
the total aggression measure, indicating that higher consumption of AAS was associated with 
higher levels of aggression. This would align well with the findings that chronic AAS use 
leads to alterations in neurochemical pathways associated with aggression (Henderson et al., 
2009) and the neurochemical points of action for AAS in brain areas implicated in regulation 
of aggression and emotions (Abdelgadir et al., 1999; Sato et al., 2004; Scordalakes & 
Rissman, 2003). Secondly, while we did not have baseline aggression levels for the 
participants in this study, a majority (65.8 %) of AAS users reported aggression as a side 
effect of AAS use. Individuals with high baseline aggressiveness experiencing no further 
increase in levels of aggression following AAS debut would conceivably not attribute this 
high aggression level to AAS use. Thirdly, AAS users without any history of drug abuse 
obtained significantly higher scores on measures of aggression than controls. The higher 
levels of aggression seen in the AAS user group could not solely be explained by the high 
prevalence of concomitant drug use among AAS users. For this group of AAS users then, 
involvement in an illegal subculture of drug criminality or aggression levels induced by 
recreational drug abuse would not be an adequate explanation for higher levels of aggression. 
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Aside from neurochemical alterations induced by AAS substances, another possible 
mechanism behind higher levels of aggression in AAS users that deserves some consideration 
is social rejection. People that, due to various experimental manipulations, considered 
themselves socially rejected in various situations have been shown to experience negative 
emotions, and to denigrate the people they felt excluded them and sometimes become angry 
and aggressive (Buckley, Winkel & Leary, 2004; Twenge & Campbell, 2003). This increase 
in aggression following social rejection has been shown de directed both at the perceived 
excluders, but also at a neutral third party individual, unrelated to the exclusion of the 
individual (Twenge et al., 2001). Use of AAS is highly stigmatized, especially in sports, so it 
can be hypothesized that social rejection can be a common experience among some AAS 
users. As this possibility has not been explicitly investigated, this could be an interesting 
avenue for future research.  
Taken together, the findings that several measures of AAS use severity correlated with 
levels of aggression, combined with previous animal research as well as the fact that many 
AAS users self-reported aggression as a side effect may lend support to the causal effect of 
AAS on aggression in humans. However, as we did not any data on baseline aggression levels 
in AAS users, firm conclusions regarding causality cannot be drawn from these findings 
alone.  
5.3 Executive functions and aggression 
The implications of the finding that AAS users perform worse than controls on measures of 
executive inhibition and executive control are of interest to the discussion about AAS and 
aggression. In our sample, AAS users displayed lower levels of executive inhibition and 
executive control and significantly higher levels of self-reported aggression, compared to 
controls.  
As described in the introduction, impairments in executive functions have been 
implicated in higher levels of aggression, and possibly more strongly associated with violent 
crimes compared to other crimes (e. g. Hancock, Tapscott & Hoaken, 2010; Marsh & 
Martinovich, 2006). An interesting possibility that deserves some further consideration, then, 
is that lower executive functions in AAS users may be part of the explanation behind the 
association between AAS use and aggression. Especially the finding that AAS users display 
higher levels of trait anger and hostility are troubling, as a combination of these factors can be 
a treacherous concoction (Finkel et al., 2012). 
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While measures of inhibition in this investigation only slightly correlated with the total 
aggression scale of the BPAQ, the weakness of this correlation may be explained by the way 
aggression was measured. The only measure of aggression included in the present 
investigation was a self-report questionnaire, meaning that aggressive behavior per se was not 
gauged. Most studies investigating the association between executive functions and 
aggression have found this association in measures of aggressive behaviors (Finkel et al., 
2012) or perpetration of crimes (Hancock, Tapscott & Hoaken, 2010). Future research should 
try to determine the association between executive functions and behavioral measures of 
aggression in AAS users utilizing behavioral paradigms or outcomes. One possible paradigm 
is the PSAP, which measures aggressive responding, operationalized as participants’ 
preference for taking points from another player instead of gaining points for themselves in a 
faux multiplayer computer game. The study by Pope, Kouri and Hudson (2000) used the 
PSAP, and significantly higher levels of aggressive responding in AAS users, without 
significant differences on the BPAQ, indicating that there may be a discrepancy between 
these two measures of aggression. 
5.4 Possible limitations 
There are several limitations that must be held in mind concerning the present study. 
One factor that may have led us to underestimate the levels of aggression in AAS 
users, is the sampling technique used for the present study. Participants were recruited from 
gyms and online AAS forums. As AAS use has been shown to be highly prevalent in prison 
populations (Lood et al., 2012; Lundholm et al., 2010; Beaver, Vaughn and Wright, 2008), 
our sample was conceivably somewhat biased as only AAS users not currently incarcerated 
were included. As incarceration rates conceivably are significantly higher among AAS using 
than non-AAS using exercisers, then our sample is not truly representative of the average 
AAS user. Aggression rates among incarcerated AAS user could be hypothesized as being 
higher than among users not currently in prison. However, as our investigation still found 
significantly higher levels of several aspects of aggression in AAS users, this may be seen as 
a testament to the robustness of this finding, rather than a detriment to the study design.  
Another weakness with the design was the matter in which aggression was measured. 
Aggression was solely assessed using a self-reports. While the questionnaire shows good 
psychometric properties (Buss & Perry, 1992), self-reports of aggression are probably subject 
to social desirability bias considering how violence and aggression are highly socially 
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unacceptable behaviors (Saunders, 1991). To corroborate this notion, AAS users who had 
ceased using AAS rated themselves as more aggressive than their currently using 
counterparts. This may indicate either that current AAS users may have underreported their 
levels of aggression, that previous AAS users overrated their levels of aggression, or both. 
Aggression is probably one of the most commonly known adverse effects of AAS, 
conceivably making it vulnerable to underreporting in current users. One investigation also 
noted that correlations between testosterone levels and aggressiveness were stronger when 
aggressiveness was rated by others (Archer, 1991). 
Another limitation with this investigation was that significance estimates were not 
corrected for by number of analyses performed. As the number of significance analyses in the 
present investigation was rather large, this may elevate the risk for type I errors. However, the 
majority of analyses were performed on measures of aggression which were quite robust. 
Concerning executive functions, a fewer number of analyses were performed, but significant 
results were not as robust as on measures of aggression.  
The nature of the phenomena of interest in this investigation, might lead us to 
underestimate the effects of AAS. We are interested in the severity of certain negative side 
effects of AAS. One possibility, then, is that users who experience the most severe side 
effects discontinue AAS after a short while. Acute psychiatric effects of AAS have been 
shown to be highly variable between individuals (Su et al., 1993; Pope, Kouri and Hudson 
2000). Some may display marked psychiatric symptoms following acute AAS use, while 
some display few side effects, if any. At this junction, then, many users who experience the 
most severe side effects, conceivably the individuals that are most reactive to AAS, might 
discontinue use of AAS due to a few bad experiences. Some, however, might not, weighing 
the benefits to muscular gain heavier than the negative side effects. The group of long-term 
AAS users, then, includes in this perspective two different classes of AAS users; those with a 
relatively benign reaction to AAS initially and users who have continued using AAS despite 
severe side effects. One interesting avenue for further research would be the developmental 
trajectories of side effects of AAS in users with a null- to mild reaction in the initial stages of 
their AAS use compared to those who are most reactive to AAS. Does long-term AAS use 
provoke negative side effects in subsamples of AAS users who initially experience no 
negative side effects, or are some AAS users blessed with a problem free AAS using career, 
independent of usage dose and duration? There is a lack of longitudinal follow-up studies of 
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side effect of AAS use. Such studies would be very informative in these matters, as well as 
for elucidating further the relationship between AAS, aggression and executive functions. 
 
5.5 Conclusions 
Taken together, the results from this study indicate that long-term AAS users display higher 
levels of anger, hostility and physical aggression than non-AAS using individuals, as well as 
poorer performance on some executive functions. Further, levels of aggression in AAS users 
were related to a more sever pattern of use, which may support the view that AAS play a 
causal role in forming aggression levels in long-term users. As this was a cross-sectional 
naturalistic observation study, firm conclusions regarding causality cannot be drawn from 
these findings alone, however. 
 While the results did not support the notion that AAS users perform worse than 
controls on task requiring cognitive flexibility, AAS users without a history of drug use 
performed significantly worse than controls on all measures of executive inhibition and 
executive control. As use pattern was not related to levels of executive functioning, however, 
the question remains open as to the reasons for these findings. A mix of reduced inhibition 
and heightened aggressiveness can be a dangerous combination that may be one of the 
explanations behind the higher levels of aggression observed in AAS users. As this is the first 
time long-term AAS use has been related to poorer performance on measures of executive 
inhibition, there is a pressing need for further investigations of this association.  
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Fig. 7 Self-reported side effects of 
AAS 
42.5 % Aggression
8.2 % Short fuse
8.2 % Irritability
6.8 % Mood swings
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A. 2 Tables 
Table 1 Descriptive statistics 
  Group Minimum Maximum Mean 
Std. 
Deviation 
Age Controls 19,0 75,0 31,8 9,5 
AAS users 21,0 56,0 33,5 8,5 
Education level** 
Controls 9,0 22,0 15,8 2,7 
AAS users 9,0 21,5 14,1 2,5 
Strength sessions per 
week 
Controls 2,0 12,0 4,7 1,5 
AAS users 0,0 17,5 4,5 2,3 
Minutes spent on 
strenght exercise per 
week* 
Controls 120,0 1200,0 463,2 242,1 
AAS users 0,0 1265,0 348,8 204,1 
Endurance sessions 
per week 
Controls 0,0 6,0 1,5 1,6 
AAS users 0,0 11,0 1,8 2,3 
Minutes spent on 
endurance exercise 
per week 
Controls 0,0 600,0 90,7 112,5 
AAS users 0,0 990,0 122,9 191,9 
Tbl. 1 Descriptive statistics for controls and AAS users. * indicates a significant difference at the 
<.05-level. ** indicates a significant difference at the <.01-level. 
Table 2 
   Differences between controls and AAS users on the BPAQ 
BPAQ Scale Group Mean 
Std. 
Deviation 
Physical 
Aggression*** 
Controls 21,80 8,64 
AAS users 33,57 12,82 
Verbal Aggression Controls 18,40 5,48 
AAS users 20,12 6,34 
Anger*** Controls 15,77 6,35 
AAS users 22,00 9,50 
Hostility** Controls 17,14 7,47 
AAS users 21,59 9,05 
Total Aggression*** Controls 73,11 19,85 
AAS users 97,28 30,11 
Tbl. 2 Group differences on the BPAQ. ** Indicates significance at 
the <.01-level, *** indicates significance at the <.001-level. 
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Table 3 
   Scores for controls and AAS users without previous or 
current drug problem 
BPAQ Scale Group Mean 
Std. 
Deviation 
Physical 
Aggression*** 
Controls 21,11 8,08 
AAS users 30,08 11,85 
Verbal 
Aggression 
Controls 18,26 5,56 
AAS users 19,34 6,28 
Anger** Controls 15,47 6,39 
AAS users 19,52 8,45 
Hostility* Controls 16,74 6,90 
AAS users 19,78 7,56 
Total 
Aggression*** 
Controls 71,58 18,21 
AAS users 88,72 27,95 
Tbl. 3 Group differences on the BPAQ.* Indicates 
significance at the <.05-level, ** indicates significance at 
the <.01-level and *** indicates significance at the <.001-
level. 
A. 3 Miscellaneous 
Syntax for Non-parametric Partial Correlation Analysis in SPSS: 
 
DATASET ACTIVATE DataSet1. 
NONPAR CORR 
  /VARIABLES= *Variable names (including covariates)* 
  /PRINT=SPEARMAN TWOTAIL NOSIG 
  /MISSING=LISTWISE 
  /MATRIX=OUT(*). 
RECODE rowtype_ ('RHO'='CORR') . 
PARTIAL CORR 
  /VARIABLES= *Variable names* BY *Covariate Variable Names* 
  /SIGNIFICANCE=TWOTAIL 
  /MISSING=LISTWISE 
  /MATRIX=IN(*). 
 
N.B. The covariate(s) to be used in the partial correlation analysis has to be included among the variables in the first analysis. 
 
